<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Suneel Kamath, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Reed E Drews, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 22, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Gastrointestinal (GI) toxicity due to chemotherapeutic drugs is a common problem in cancer patients. The high proliferation index of the GI mucosa makes it particularly susceptible to toxicity from chemotherapy [<a href="#rid1">1</a>]. The specific chemotherapy-related GI complications that are reviewed here include diarrhea, constipation, and intestinal perforation. Evaluation and management of patients with acute chemotherapy-related diarrhea is discussed separately, as is enterotoxicity related to immunotherapy with checkpoint inhibitors, chemotherapy-induced oral toxicity (mucositis), and chemotherapy-induced nausea and vomiting. (See  <a class="medical medical_review" href="/d/html/98342.html" rel="external">"Management of acute chemotherapy-related diarrhea"</a> and  <a class="medical medical_review" href="/d/html/1152.html" rel="external">"Oral toxicity associated with systemic anticancer therapy"</a> and  <a class="medical medical_review" href="/d/html/138429.html" rel="external">"Immune checkpoint inhibitor colitis"</a> and  <a class="medical medical_review" href="/d/html/1150.html" rel="external">"Pathophysiology and prediction of chemotherapy-induced nausea and vomiting"</a> and  <a class="medical medical_review" href="/d/html/1151.html" rel="external">"Prevention of chemotherapy-induced nausea and vomiting in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DIARRHEA</span><span class="headingEndMark"> — </span>Chemotherapy-related diarrhea (CRD) is most commonly described with fluoropyrimidines (particularly <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> [FU] and <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>) and <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>. Diarrhea is the dose-limiting and major toxicity of regimens containing a fluoropyrimidine with irinotecan. However, in addition to conventional cytotoxic drugs, many molecularly targeted agents (including tyrosine kinase inhibitors [TKIs] and monoclonal antibodies) are also associated with CRD. (See <a class="local">'Risk with conventional cytotoxic agents'</a> below.)</p><p class="headingAnchor" id="H612325409"><span class="h2">Pathogenesis/mechanisms</span><span class="headingEndMark"> — </span>CRD generally occurs through three major mechanisms: increased secretion of electrolytes caused by luminal secretagogues or reduced absorptive capacity (due to surgery or epithelial damage), called secretory diarrhea; increased intraluminal osmotic substances leading to osmotic diarrhea; or altered gastrointestinal (GI) motility. Direct ischemic mucosal damage is reported in patients treated with agents targeting the vascular endothelial growth factor (VEGF), while an immune-mediated colitis is responsible for diarrhea with immune checkpoint inhibitors.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secretory diarrhea</strong> – Both FU and <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> cause acute damage to the intestinal mucosa, leading to loss of epithelium [<a href="#rid2">2,3</a>]. FU induces mitotic arrest of crypt cells, leading to an increase in the ratio of immature secretory crypt cells to mature villous enterocytes [<a href="#rid2">2</a>]. The increased volume of fluid that leaves the small bowel exceeds the absorptive capacity of the colon, leading to clinically significant diarrhea. Irinotecan produces mucosal changes associated with apoptosis, such as epithelial vacuolization and goblet cell hyperplasia, suggestive of mucin hypersecretion [<a href="#rid3">3-5</a>]. These changes appear related to the accumulation of the active metabolite of irinotecan, SN-38, in the intestinal mucosa [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1">Up to 50 percent of patients treated with TKIs experience diarrhea [<a href="#rid7">7</a>]. It is thought that the diarrhea occurs through multiple mechanisms. Increased chloride secretion caused by dysregulation of the epidermal growth factor receptor (EGFR) signaling pathway [<a href="#rid8">8,9</a>], colonic crypt damage, gut dysmotility, and alteration in gut microbiota have been proposed. Many cytotoxic chemotherapeutic agents and other classes of antineoplastic drugs cause diarrhea due to damage to the intestinal mucosa, leading to a loss of absorptive surfaces.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Osmotic diarrhea</strong> – Damage to the brush border enzyme system within the epithelium can cause osmotic diarrhea due to inadequate digestion. Approximately 10 percent of patients being treated with FU have decreased expression of the enzyme lactase in their intestinal brush border, leading to lactose intolerance [<a href="#rid10">10,11</a>]. The D-xylose absorption test has been reported to be abnormal in several patients undergoing chemotherapy [<a href="#rid12">12,13</a>], suggesting the presence of carbohydrate malabsorption (such as sucrose, fructose, or even complex polysaccharides). In one study, consumption of a diet high in lactose was associated with increased diarrhea in the setting of adjuvant FU, especially when consumption of fermentable oligo-, di- and monosaccharides and polyols (FODMAP) foods was also high [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Altered intestinal motility</strong> – Early-onset diarrhea with <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> occurs during or within several hours of drug infusion in 45 to 50 percent of patients and is cholinergically mediated [<a href="#rid15">15</a>]. By contrast, late irinotecan-associated diarrhea is not cholinergically mediated and, instead, appears to be multifactorial, with contributions from dysmotility and secretory factors, as well as a direct toxic effect on the intestinal mucosa. (See <a class="local">'Irinotecan'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs that target angiogenesis</strong> – Therapies that target angiogenesis, including monoclonal antibodies against vascular endothelial growth factor (VEGF) and its receptor, and antiangiogenic TKIs are associated with GI tract perforation [<a href="#rid16">16,17</a>]. The mechanism by which this happens has not been proven, but proposed mechanisms include intestinal wall disruption (ulceration) in areas of tumor necrosis, disturbed platelet-endothelial cell homeostasis causing submucosal inflammation and subsequent ulcer formation, impaired healing of pathologic, chemotherapy-induced or surgical bowel injury, and mesenteric ischemia from thrombosis and/or vasoconstriction; all of these may result in diarrhea as well. Randomized trials of <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> added to chemotherapy for colorectal cancer have resulted in small increases in severe diarrhea, but this has not been observed in other tumor types, suggesting that bevacizumab may not be causing diarrhea directly but, instead, diarrhea may be caused by one of the indirect mechanisms mentioned above [<a href="#rid18">18,19</a>].</p><p></p><p class="bulletIndent1">In a study of patients who developed diarrhea in the setting of antiangiogenic therapy with concomitant chemotherapy, normal endoscopic findings were more common in patients with diarrhea alone than in those with diarrhea plus symptoms of enterocolitis such as blood or mucus in stool, pain, fever, or abdominal distension [<a href="#rid20">20</a>]. Endoscopic abnormalities included ulcerations and nonulcerative inflammation. Patients with abnormal endoscopic findings were more likely to have active inflammation on histology. (See <a class="local">'Intestinal perforation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Checkpoint inhibitor immunotherapy</strong> – <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">Ipilimumab</a> is a monoclonal antibody directed against CTLA-4, an immune checkpoint molecule on the T-cell surface. <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">Pembrolizumab</a>, <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>, <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a>, <a class="drug drug_general" data-topicid="112994" href="/d/drug information/112994.html" rel="external">durvalumab</a>, <a class="drug drug_general" data-topicid="112481" href="/d/drug information/112481.html" rel="external">avelumab</a>, and <a class="drug drug_general" data-topicid="119172" href="/d/drug information/119172.html" rel="external">cemiplimab</a> are monoclonal antibodies directed against the programmed cell death 1 protein (PD-1) or its ligand (PD-L1). These drugs are approved for multiple indications, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), bladder cancer, Hodgkin lymphoma, and many others. (See  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation"</a> and  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma"</a> and  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation", section on 'Ipilimumab'</a> and  <a class="medical medical_review" href="/d/html/90312.html" rel="external">"Initial management of advanced non-small cell lung cancer lacking a driver mutation", section on 'Nivolumab plus ipilimumab, with or without chemotherapy'</a>.)</p><p></p><p class="bulletIndent1">The presumed mechanism of action for checkpoint inhibitor immunotherapy is to reduce tolerance to tumor-associated antigens, leading to increased antitumor immune cell activity. At the same time, this may result in decreased tolerance to self-antigens. A wide range of immune-mediated adverse events have been observed, including enterocolitis, which can be serious or life-threatening. It is critical to recognize that treatment of diarrhea caused by immune checkpoint inhibitors may require systemic glucocorticoids. The manifestations and management of checkpoint inhibitor immunotherapy-induced enterocolitis are discussed separately. (See  <a class="medical medical_review" href="/d/html/138429.html" rel="external">"Immune checkpoint inhibitor colitis"</a>.)</p><p></p><p class="headingAnchor" id="H343979093"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Typical CRD typically begins with an increasing frequency of bowel movements and/or a loosening of stool consistency. Excessive gas and/or intestinal cramping commonly accompanies CRD. As the CRD progresses, it can become severe, with frequent watery stools. With some drugs (eg, <a class="drug drug_general" data-topicid="119167" href="/d/drug information/119167.html" rel="external">duvelisib</a>), the stool may contain mucus or blood. Even mild CRD can have a profound impact on quality of life, as many chemotherapies are administered for several months to years, and thus CRD should be managed aggressively in the outpatient setting.</p><p>CRD can be debilitating and, in some cases, life-threatening. Findings in such patients include volume depletion, acute kidney injury, and electrolyte disorders, such as hypokalemia, metabolic acidosis, and depending upon water intake, hyponatremia (increased water intake that cannot be excreted because of the hypovolemic stimulus to release of antidiuretic hormone) or hypernatremia (insufficient water intake to replace losses). Infection, including life-threatening sepsis, can result due to a breach of the intestinal mucosa, which is worsened in the setting of chemotherapy-induced immunosuppression.</p><p>Given the risk for dehydration and infection, severe CRD frequently requires hospital admission for adequate supportive care. Other sequelae of CRD include increased cost of care, reduced quality of life, treatment delays, and diminished compliance with treatment regimens, which may compromise long-term outcomes if the chemotherapy is being administered with curative intent [<a href="#rid21">21</a>].</p><p>The severity of CRD is often described using the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fctep.cancer.gov%2FprotocolDevelopment%2Felectronic_applications%2Fctc.htm&amp;token=L1PKi7ksomh1JqUfTKWNe61gdDEj7%2FEN0gFsM2jnisnZ9aDYBZ%2FnKF0Y6hAnywy9MOvaze9hPSMvHYdMdeBk6asiYcR9Y9yHOUcUYVkBUtI%3D&amp;TOPIC_ID=2824" target="_blank">National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)</a> grades; the latest version is outlined in the table  (<a class="graphic graphic_table graphicRef65649" href="/d/graphic/65649.html" rel="external">table 1</a>). Severity is determined by an increase in the number of stools per day or ostomy output compared with baseline, the need for hospitalization, and the effect on activities of self-care. It is critical to ascertain the patient's baseline bowel pattern when grading the severity of diarrhea.</p><p>Assessment of patients with acute CRD is addressed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/98342.html" rel="external">"Management of acute chemotherapy-related diarrhea", section on 'Clinical assessment'</a>.)</p><p class="headingAnchor" id="H3275962162"><span class="h3">Colitis syndromes that may arise in patients treated with chemotherapy</span><span class="headingEndMark"> — </span>Patients undergoing chemotherapy may develop several types of colitis. (See  <a class="medical medical_review" href="/d/html/98342.html" rel="external">"Management of acute chemotherapy-related diarrhea", section on 'Differential diagnosis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neutropenic enterocolitis</strong> – Neutropenic enterocolitis (a form of necrotizing enterocolitis or typhlitis) is one of the most common GI complications in leukemia patients who are undergoing induction therapy and can occur in other malignancies or following stem-cell-supported high-dose chemotherapy [<a href="#rid22">22,23</a>].</p><p></p><p class="bulletIndent1">Neutropenic enterocolitis should be considered in any severely neutropenic patient (particularly absolute neutrophil count &lt;500 cells/microL) who presents with fever and abdominal pain. The location of abdominal pain is often in the right lower quadrant, and constitutional symptoms such as fever frequently appear during the third week (median 17 days) after receiving cytotoxic chemotherapy, at a time when neutropenia is most profound. Additional symptoms may include abdominal distension, cramping, tenderness, nausea, vomiting, watery or bloody diarrhea, and frank hematochezia. The appearance on computed tomography (CT) is characteristic  (<a class="graphic graphic_picture graphicRef129146" href="/d/graphic/129146.html" rel="external">picture 1</a>).</p><p></p><p class="bulletIndent1">The pathogenesis, risk factors, diagnosis, and management of patients with neutropenic enterocolitis are discussed separately. (See  <a class="medical medical_review" href="/d/html/2690.html" rel="external">"Neutropenic enterocolitis (typhlitis)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ischemic colitis</strong> – A small number of cases of ischemic colitis have been reported with docetaxel-containing regimens in patients with metastatic breast cancer, including 3 of 14 patients in a phase I study of <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> plus <a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">vinorelbine</a> [<a href="#rid24">24,25</a>]. The typical onset is 4 to 10 days following administration. Patients with acute colonic ischemia usually present with rapid onset of mild abdominal pain and tenderness over the affected bowel, commonly on the left side of the abdomen. Mild to moderate amounts of rectal bleeding or bloody diarrhea typically develop within 24 hours of the onset of abdominal pain. (See  <a class="medical medical_review" href="/d/html/2559.html" rel="external">"Overview of intestinal ischemia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Clostridioides difficile</em></strong><strong>-associated colitis</strong> – <em>Clostridioides difficile</em> colitis is a common problem in patients with cancer, mostly due to the high rate of oral antibiotic use and hospitalization. However, several reports have described this complication in patients without any prior antibiotic use following chemotherapy [<a href="#rid26">26-28</a>]. The proposed mechanism is chemotherapy-induced intestinal damage that facilitates the proliferation of <em>C. difficile</em>. Frequent occurrence of <em>C. difficile</em>-related diarrheal episodes has been reported in patients treated with paclitaxel-containing regimens, especially with the use of "dose-dense" regimens [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1">Watery diarrhea is the cardinal symptom of <em>C. difficile</em>-associated diarrhea with colitis (≥3 loose stools in 24 hours). Other manifestations include lower abdominal pain and cramping, low-grade fever, nausea, anorexia, and leukocytosis. Ileus can occur in severe cases. The spectrum of illness varies from mild to fulminant; management is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2699.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2698.html" rel="external">"<i>Clostridioides difficile</i> infection in adults: Treatment and prevention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphocytic colitis</strong> – Patients receiving treatment with <a class="drug drug_general" data-topicid="17100" href="/d/drug information/17100.html" rel="external">aflibercept</a> may develop lymphocytic colitis (microscopic colitis), for which specific treatment with <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> may be beneficial [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/4071.html" rel="external">"Microscopic (lymphocytic and collagenous) colitis: Clinical manifestations, diagnosis, and management", section on 'Glucocorticoids for active disease'</a>.)</p><p></p><p><strong>Differential diagnosis</strong> — Patients who develop acute diarrhea during chemotherapy may also suffer from organic causes of diarrhea, such as bacterial overgrowth, fat or bile acid malabsorption, intake of excess quantities of <a class="drug drug_general" data-topicid="9940" href="/d/drug information/9940.html" rel="external">sorbitol</a> or lactose intolerance, and inflammatory and infectious causes, which should not be overlooked.</p><p>Clinical manifestations, differential diagnosis, and management of acute chemotherapy-related diarrhea are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/98342.html" rel="external">"Management of acute chemotherapy-related diarrhea"</a>.)</p><p class="headingAnchor" id="H1730603"><span class="h2">Risk with conventional cytotoxic agents</span></p><p class="headingAnchor" id="H5"><span class="h3">Fluorouracil</span><span class="headingEndMark"> — </span>One of the main dose-limiting side effects of fluoropyrimidines such as FU (and its oral prodrugs <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> and ftorafur-uracil [UFT]) is diarrhea. Both the therapeutic efficacy and frequency of diarrhea associated with FU are increased when given concurrently with <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> (LV), a <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> derivative. Diarrhea is also schedule-dependent. The highest frequency of diarrhea occurs with bolus rather than continuous 24-hour infusion of FU/LV for up to five days, particularly with weekly bolus administration, but it can occur with all schedules of administration [<a href="#rid31">31-36</a>]. (See  <a class="medical medical_review" href="/d/html/2471.html" rel="external">"Adjuvant therapy for resected stage III (node-positive) colon cancer", section on 'Less fit patients or a contraindication to oxaliplatin'</a> and  <a class="medical medical_review" href="/d/html/2512.html" rel="external">"Therapy for metastatic colorectal cancer in older adult patients and those with a poor performance status", section on 'Fluoropyrimidine monotherapy'</a>.)</p><p>In multiple reports of weekly FU/LV, diarrhea was seen in up to 50 percent of patients, half of whom required hospitalization for intravenous (IV) fluids [<a href="#rid31">31,32,35</a>]. In one series, 11 of 221 patients (5 percent) died of treatment-related toxicity, most of them older adult patients with concomitant leukopenia and sepsis [<a href="#rid35">35</a>]. Based upon these observations, treatment is routinely withheld for grade 2 or worse  (<a class="graphic graphic_table graphicRef65649" href="/d/graphic/65649.html" rel="external">table 1</a>) diarrhea and not restarted until diarrhea resolves, an approach that has led to a significant reduction in severe enterotoxicity with these regimens. (See  <a class="medical medical_review" href="/d/html/98342.html" rel="external">"Management of acute chemotherapy-related diarrhea", section on 'Restarting chemotherapy'</a>.)</p><p>No risk factor can reliably predict the development of diarrhea with FU therapy, but the risk is increased in the presence of an unresected primary tumor, shortened bowel resulting from previous surgery, previous episodes of CRD, treatment during the summer season [<a href="#rid37">37,38</a>], and when bolus FU and LV are combined with <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> [<a href="#rid39">39</a>] or <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>. (See <a class="local">'IFL'</a> below.)</p><p>Women appear to suffer more toxicity from FU than men for unclear reasons [<a href="#rid40">40,41</a>]. In a meta-analysis of over 2400 patients enrolled in five trials (three for advanced disease, two in the adjuvant setting), significantly more women experienced ≥grade 3 toxicity during therapy than did men (50 versus 40 percent) [<a href="#rid40">40</a>]. All of these trials used a five-day bolus schedule of FU and LV. These data suggest that women may be better served by less toxic administration schedules of FU, including short-term infusional regimens. (See  <a class="medical medical_review" href="/d/html/2471.html" rel="external">"Adjuvant therapy for resected stage III (node-positive) colon cancer"</a> and  <a class="medical medical_review" href="/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Not candidates for intensive therapy'</a>.)</p><p class="headingAnchor" id="H6"><span class="h4">Predictive markers</span><span class="headingEndMark"> — </span>Early detection of patients who are at risk of developing life-threatening toxicity from fluoropyrimidines based upon predictive markers might allow dose reduction or selection of an alternative treatment regimen. The two most-studied predictive factors are enzymatic activity of dihydropyrimidine dehydrogenase (DPD) and thymidylate synthetase  (<a class="graphic graphic_table graphicRef109665" href="/d/graphic/109665.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H717960356"><span class="h5">DPD deficiency</span><span class="headingEndMark"> — </span>Dihydropyrimidine dehydrogenase (DPD), the first of three enzymes in the fluoropyrimidine metabolic pathway, is the rate-limiting enzyme in FU catabolism. Enzyme activity varies widely, with most of the variability arising from genetic polymorphisms in the dihydropyrimidine dehydrogenase gene (<em>DPYD</em>). Patients who are partially or totally deficient in DPD activity cannot adequately degrade fluoropyrimidines, leading to an increased risk of severe, sometimes fatal, toxicity. In patients with even partial DPD deficiency, administration of a fluoropyrimidine can lead to life-threatening complications, including severe diarrhea, mucositis, and pancytopenia [<a href="#rid42">42-50</a>]. Nausea, vomiting, rectal bleeding, volume depletion, skin changes, neurologic abnormalities (cerebellar ataxia, cognitive dysfunction, altered level of consciousness), and cardiotoxicity may also occur. (See  <a class="medical medical_review" href="/d/html/89348.html" rel="external">"Fluoropyrimidine-associated cardiotoxicity: Incidence, clinical manifestations, mechanisms, and management", section on 'DPYD polymorphisms'</a>.)</p><p>Molecular analysis of patients with DPD deficiency has identified over 128 mutations and polymorphisms in the <em>DPYD</em> gene that may result in partial or total loss of DPD activity [<a href="#rid51">51-53</a>]. Only four have been consistently associated with a marked decrease in DPD activity and enhanced fluoropyrimidine toxicity, including <em>DPYD</em>*2A single-nucleotide polymorphism (SNP) [<a href="#rid51">51,54-63</a>], <em>DPYD</em>*13 SNP [<a href="#rid51">51,53,64</a>], <em>DPYD</em>*9B SNP [<a href="#rid51">51,53,63</a>], and a collection of SNPs termed HapB3 [<a href="#rid65">65-67</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><em>DPYD</em>*2A is a single-nucleotide polymorphism (SNP); splice site variant IVS14+1G&gt;A with the nucleotide change 1905+1G&gt;A, resulting in an exon 14 deletion [del]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>DPYD</em>*13 SNP, has a nucleotide change 1679T&gt;G, with resultant amino acid substitution I560S</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>DPYD</em>*9B SNP, has a nucleotide change c.2846A&gt;T, with resultant amino acid substitution D949V</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HapB3 is composed of three intronic variants (c.483+18G&gt;A, c.680+139G&gt;A, and c.959-51T&gt;C), and one synonymous variant (c.1236G&gt;A); there is another deep intronic variant in the <em>DPYD</em> g<em>e</em>ne (c.1129-5923C&gt;G) in tight linkage with HapB3, and this polymorphism (c.1129-5923C&gt;G/HapB3) may contribute to fluoropyrimidine toxicity. In Europeans, c.1129-5923C&gt;G/HapB3 is the most common <em>DPYD </em>variant, with carrier frequencies of approximately 5 percent [<a href="#rid68">68</a>]. However, the effects of this variant are modest [<a href="#rid69">69</a>], which probably explains the disparate reports on its influence on FU toxicity [<a href="#rid64">64-67,70</a>].</p><p></p><p>Although complete DPD deficiency is rare (and usually associated with homozygosity for one of the alleles associated with reduced enzyme activity), partial deficiencies due to the inheritance of one high-risk allele are more common, particularly in Black women. These demographic differences can be illustrated by an analysis of enzyme levels from 258 normal volunteers [<a href="#rid71">71</a>]. No person had complete DPD deficiency, while partial DPD deficiency was present in 12.3, 4.0, 3.5, and 1.9 percent of Black women and men, and White women and men, respectively. Only four (1.6 percent) volunteers (three Black women and one Black man) had profound DPD deficiency.</p><p>Despite the association of one of these high-risk alleles with severe CRD, we do not routinely test <em>DPYD</em> genotype for all patients initiating fluoropyrimidine therapy. In the United States, one of the three high-risk alleles, <em>DPYD</em>*2A, *13, and *9B, is present in fewer than 10 percent of patients in most populations, and inheritance of a high-risk allele is not always associated with life-threatening toxicity (ie, the positive predictive value of having one of these alleles on the risk of severe toxicity is variable). Inheritance of one of these high-risk alleles does not account for the majority of FU-associated severe toxicity, which is estimated to occur in 15 to 30 percent of treated patients (ie, sensitivity is limited). Finally, even if preemptive pharmacogenomics testing is done and these high-risk alleles are not detected, patients can still have life-threatening toxicity (ie, the specificity is limited). These issues can be illustrated by the following data:</p><p class="bulletIndent1"><span class="glyph">●</span>In one series, one of the three high-risk <em>DPYD</em> variants was found in only 30 percent of FU-treated patients (13 of 44) who developed grade 3 or 4 toxicity [<a href="#rid51">51</a>]. Similarly, a systematic review by the Clinical Pharmacogenetics Implementation Consortium (CPIC) concluded that between 23 and 38 percent of severe fluoropyrimidine toxicity could be attributed to <em>DPYD</em> variants (clinical sensitivity approximately 31 percent) [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective study of 683 patients receiving FU monotherapy, grade 3 or 4 toxicity occurred in 16 percent, and genotyping revealed the <em>DPYD</em>*2A allele in only 5 percent of those with treatment-related toxicity [<a href="#rid56">56</a>]. Furthermore, fewer than half of those who had the <em>DPYD</em>*2A allele developed grade 3 or 4 toxicity (positive predictive value 46 percent). Of interest, there was a gene-sex interaction, resulting in an odds ratio (OR) of 41.8 for male patients but only 1.33 for female patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another series of 430 patients initiating therapy with FU or <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> for any tumor type, 24 of the 104 patients experiencing grade 3 or 4 toxicity in the first four cycles of therapy (23 percent) were found to have one of four high-risk variant alleles (<em>DPYD</em>*2A, *13, *9B, and one other high-risk allele, 1601G&gt;A) [<a href="#rid61">61</a>]. Only 6 percent of the entire cohort had one of these four variants. In contrast to the prior series, the positive predictive value of having inherited any of these four high-risk alleles for severe (grade 3 or 4) diarrhea, mucositis, or myelosuppression during the first four cycles of therapy in this study was &gt;99 percent.</p><p></p><p>Some of the inconsistency in study results may be attributable to variations in the treatment regimens across studies. The <em>DPYD</em>*2A allele has been associated with toxicity more frequently when FU was administered in combination with other chemotherapeutic agents rather than as monotherapy [<a href="#rid72">72</a>]. Furthermore, there appears to be significant interethnic differences in frequency and genetic constitution of DPD deficiency [<a href="#rid73">73</a>].</p><p>A major issue is that inheritance of one of these high-risk alleles does not account for all cases of DPD deficiency. Impaired DPD activity has been detected in some patients with normal wild-type <em>DPYD</em> alleles, presumably due to epigenetic mechanisms, including microRNAs, that regulate enzyme activity [<a href="#rid74">74,75</a>].</p><p>Despite these difficulties, the potential benefits of identifying patients who have inherited one of these three high-risk alleles in terms of reducing treatment-related toxicity and improving the cost-effectiveness of care can be illustrated by the following reports:</p><p class="bulletIndent1"><span class="glyph">●</span>In a report of data from a large cohort of patients with stage III colon cancer who were enrolled on the adjuvant NCCTG N0147 trial, the frequency of finding one of the three high-risk <em>DPYD</em> alleles was low overall; of the 2886 patients who were genotyped, 27 (0.9 percent), 4 (0.1 percent), and 32 (1.1 percent) carried the <em>DPYD</em>*2A, *13, and *9B variants, respectively [<a href="#rid76">76</a>]. However, of the 2594 patients with complete adverse event data, grade 3 or 4 adverse events developed in 22 of the 25 patients with the *2A variant (88 percent positive predictive value), in two of four *13 carriers (50 percent), and in 22 of 27 *9B carriers (82 percent). The *2A variant was significantly associated with nausea and vomiting and neutropenia but not diarrhea, while the *9B variant was significantly associated with dehydration, diarrhea, neutropenia, and thrombocytopenia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a more recent series, 1181 patients initiating fluoropyrimidine therapy were prospectively screened for the four most common <em>DPYD</em> variants found in the Netherlands (<em>DPYD</em>*2A, c.2846A&gt;T, c.1679T&gt;G, and c.1236G&gt;A) prior to initiating therapy; 85 patients (8 percent of total) were heterozygous <em>DPYD</em> variant allele carriers and were treated with a reduced dose of fluoropyrimidine [<a href="#rid77">77</a>]. The risk of grade 3 or worse adverse events was 39 percent in patients with <em>DPYD</em> variant alleles compared with 23 percent in <em>DPYD</em> wild-type patients. In pharmacokinetic analyses, mean drug and therapeutic metabolite exposure was similar between <em>DPYD</em> variant allele carriers treated with a reduced dose and wild-type patients. Interestingly, there was no correlation between DPD enzyme activity and the occurrence of severe fluoropyrimidine-related toxicity in <em>DPYD</em> variant allele-carrying patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a cost-effectiveness analysis of screening patients intended to receive fluoropyrimidine-based chemotherapy for the four most common <em>DPYD</em> variants found in the Netherlands (<em>DPYD</em>*2A, c.2846A&gt;T, c.1679T&gt;G, and c.1236G&gt;A), the expected total costs for the screening strategy were 2599 euros per patient compared with 2650 euros per patient for the non-screening strategy [<a href="#rid78">78</a>]. The study also found that the total costs of hospitalization for five <em>DPYD</em> variant allele carriers that experienced severe toxicity were much higher than prospectively screening the whole study population (232,061 versus 23,718 euros).</p><p></p><p>As noted above, the <em>DPYD</em>*2A, <em>DPYD</em>*13, <em>DPYD</em>*9B, and HapB3 variants are the most commonly reported high-risk <em>DPYD</em> variants. Other alleles with equivocal effects on the likelihood of fluoropyrimidine-related toxicity include polymorphisms in the <em>DPYD</em>*4 allele and the <em>DPYD</em>*5 allele [<a href="#rid54">54,62,65,77</a>].</p><p>If a high-risk<em> DPYD</em> variant is identified prior to treatment, guidelines for fluoropyrimidine dosing are available from the CPIC  (<a class="graphic graphic_table graphicRef91548" href="/d/graphic/91548.html" rel="external">table 3</a>) [<a href="#rid79">79,80</a>]. However, they do not provide recommendations on whether and when to perform pharmacogenomics testing. Given the low frequency of finding a predictive allele and the low sensitivity (ie, patients who lack one of these high-risk<em> DPYD</em> variants may still suffer grade 3 or 4 fluoropyrimidine-related toxicity), preemptive genetic testing of all patients due to receive a fluoropyrimidine in order to identify those with DPD deficiency is controversial and not widely practiced [<a href="#rid81">81</a>]. The US Food and Drug Administration (FDA) does not currently require pharmacogenetic testing before fluoropyrimidine administration. In the United States, testing is usually reserved for patients who develop unusually early, severe, treatment-related toxicity (diarrhea, mucositis, myelosuppression, neurotoxicity, cardiotoxicity) in the first cycle of fluoropyrimidine therapy.</p><p>On the other hand, in March 2020, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) recommended all patients planned to receive any fluoropyrimidine therapy undergo pharmacogenomics testing prior to starting therapy [<a href="#rid82">82</a>], and this approach has been adopted in updated guidelines for management of localized colon cancer from the European Society for Medical Oncology (ESMO) [<a href="#rid83">83</a>]. This subject is discussed in detail below. (See <a class="local">'Testing for DPYD and TYMS variants'</a> below.)</p><p class="headingAnchor" id="H44530683"><span class="h5">TYMS gene variations</span><span class="headingEndMark"> — </span>In addition to <em>DPYD</em>, high-risk polymorphisms in the thymidylate synthetase gene (<em>TYMS</em>) may be associated with a 1.4- to 2.4-fold increase in the risk of severe toxicity from FU-based chemotherapy; however, the data are less certain than with the high-risk <em>DPYD</em> genotypes.</p><p>Thymidylate synthetase (TS), a critical enzyme for thymidine production, is potently inhibited by FU. The important polymorphisms that might influence fluoropyrimidine toxicity are outlined in the table  (<a class="graphic graphic_table graphicRef109665" href="/d/graphic/109665.html" rel="external">table 2</a>) and are described in detail in the following sections:</p><p class="bulletIndent1"><span class="glyph">●</span>Expression of <em>TYMS</em> is regulated by transcription factors that bind to the promoter region. The 5' untranslated region (UTR) contains a variable number of 28 bp tandem repeats (VNTRs), which can stimulate transcriptional activity. The vast majority of individuals carry <em>TYMS</em> alleles that contain two or three repeats in this promoter region, designated 2R and 3R [<a href="#rid84">84,85</a>]. Patients who are homozygous for the triple repeat (3R/3R) have a greater number of binding sites for transcription factor and higher TS levels compared with those who are 2R/2R or 3R/2R; conversely, 2R/2R homozygotes have low TS levels in normal tissues and may be at a greater risk of FU cytotoxicity. Notably, patients who overexpress TS have relative resistance to fluoropyrimidines.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An SNP has been described in the 12<sup>th</sup> nucleotide of the second repeat of the 3R allele, which abolishes a promoter binding site in the 3R allele (designated the 3RC allele) and leads to markedly reduced TS activity [<a href="#rid84">84,86-89</a>]. Others describe greater toxicity with a similar substitution of cytosine for guanine at the 12<sup>th</sup> nucleotide in two 28 bp repeats in the 5' UTR (designated 2RC) [<a href="#rid88">88,90</a>].</p><p></p><p>The available data linking these polymorphisms to increased fluoropyrimidine toxicity are conflicting, as evidenced by the following reports:</p><p class="bulletIndent1"><span class="glyph">●</span>The 2R/2R genotype has been associated with greater toxicity in many [<a href="#rid85">85,91-93</a>], but not all [<a href="#rid61">61,93,94</a>], studies. Even in positive studies, the sensitivity and positive predictive value appear to be limited. As an example, in three studies totaling 200 unselected patients who received FU, 44 (22 percent) developed grade 3 or 4 toxicity [<a href="#rid85">85,91,92</a>]. Only 13 of the 44 had the high-risk 2R/2R genotype (sensitivity 30 percent), while of the 25 patients who inherited the 2R/2R high-risk genotype, only 13 developed grade 3 or 4 toxicity (positive predictive value 52 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inheritance of a high-risk 2RC allele has been associated with an increase in toxicity [<a href="#rid88">88,90</a>]. In a series of 1613 patients, 28 had the 2RC variant allele (1.7 percent), and 20 had a high-risk genotype (2RG/2RC, 3RC/2RC, and 2RC/2RC) [<a href="#rid90">90</a>]. Both early severe toxicity and toxicity-related hospitalization were more frequent in risk-associated genotype carriers (OR 3.0 [95% CI 1.04-8.93] and 3.8 [95% CI 1.19-11.9], respectively).</p><p></p><p class="headingAnchor" id="H44530527"><span class="h5">Other predictive markers</span><span class="headingEndMark"> — </span>The contribution of other genetic and nongenetic factors has not been well studied [<a href="#rid95">95,96</a>]. At least some data suggest marked regional differences in tolerability of fluoropyrimidines, with the highest toxicity rates in the United States and the lowest in East Asia [<a href="#rid97">97</a>]. This may be due, in part, to differences in dietary <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> intake [<a href="#rid97">97,98</a>]. Reduced folates (such as LV) stabilize the binding of the FU metabolite fluorodeoxyuridine monophosphate to thymidylate synthetase, enhancing the response to fluoropyrimidine therapy [<a href="#rid99">99</a>] but also increasing toxicity. Higher pretreatment serum folate levels have also been linked to greater toxicity from <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>, an orally active prodrug of FU [<a href="#rid100">100</a>]. (See <a class="local">'Capecitabine'</a> below.)</p><p class="headingAnchor" id="H44530323"><span class="h4">Testing for DPYD and TYMS variants</span><span class="headingEndMark"> — </span>We do not routinely implement testing for <em>DPYD</em> and/or <em>TYMS</em> genotype for all patients initiating fluoropyrimidine therapy, but test for the panel of DPD alleles (rather than just <em>DPYD</em>*2A) in patients who have had severe and unexpected toxicity from fluoropyrimidines. <em>TYMS</em> genotyping could be included along with <em>DPYD </em>testing, where available, for patients who have had severe reactions to fluoropyrimidine therapy  (<a class="graphic graphic_table graphicRef109665" href="/d/graphic/109665.html" rel="external">table 2</a>).</p><p>Pharmacogenetic profiling has the potential to identify patients who may experience severe adverse effects with fluoropyrimidines, but the clinical utility of preemptive testing remains controversial (reviewed in [<a href="#rid101">101</a>]). Some authors suggest genotype testing prior to initiating fluoropyrimidine therapy in all patients, and some institutions have adopted this approach [<a href="#rid102">102-106</a>]. Clinical guidelines are disparate:</p><p class="bulletIndent1"><span class="glyph">●</span>Preemptive testing for <em>DPYD</em> variants is now recommended by the EMA [<a href="#rid82">82</a>] but not the FDA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preemptive testing has been endorsed (at least prior to administration of adjuvant fluoropyrimidine-containing chemotherapy for localized colon cancer) by ESMO [<a href="#rid83">83</a>], but not by the National Comprehensive Cancer Network (NCCN).</p><p></p><p>Given these issues, not surprisingly, clinical adoption of pretreatme<em>nt DPYD</em> testing has been extremely limited in the United States [<a href="#rid107">107</a>].</p><p>Although fatal toxicity from fluoropyrimidine therapy is quite rare, preemptive testing for the presence of these four DPD alleles (<em>DPYD</em>*2A, c.2846A&gt;T, c.1679T&gt;G, and c.1236G&gt;A) may prevent severe toxicity and appears to be at least cost-neutral in a European population [<a href="#rid78">78</a>]. An important point is that there are no prospective randomized trials that demonstrate improved toxicity without compromise of efficacy in patients who are preemptively screened versus not screened using any assay for DPD activity, including pharmacogenetic testing for high-risk <em>DPYD</em> and <em>TYMS</em> variants.</p><p>Preemptive genotyping may not be covered by insurance in the United States, and the turn-around time for various laboratories is listed as up to 10 days.</p><p>At many institutions, including those of several of the authors and editors associated with this review, genotyping is reserved for those patients who have unexpected toxicity (myelosuppression, mucositis, diarrhea, neurotoxicity, cardiotoxicity) during the first few cycles of fluoropyrimidine therapy. These patients should be suspected of having an at-risk <em>DPYD</em> or <em>TYMS</em> mutation, for which testing for at-risk mutations in <em>DPYD</em> and <em>TYMS</em> is reasonable, as dosing recommendations for <em>DPYD</em> mutation carriers are available from CPIC, and because identification of at-risk mutations may be of use if family members are to be treated in the future with fluoropyrimidines. Any patient who experiences severe toxicity following treatment with a fluoropyrimidine, regardless of whether they have an identified at-risk variant in <em>DPYD</em> or <em>TYMS</em> will require a significant dose reduction if continued treatment is planned.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phenotypic testing as an alternative to genotyping</strong> – As an alternative to genotyping, phenotypic testing may be used to assess DPD functionality; DPD deficiency is reflected by a reduced ratio of dihydrouracil: uracil in plasma, or higher levels of uracil [<a href="#rid108">108-110</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One prospective study of 59 patients with GI malignancies assessed DPD function in all patients prior to their initial FU dose by measuring the ratio of dihydrouracil to uracil in blood as a surrogate test. Patients with reduced DPD activity (a dihydrouracil:uracil ratio &lt;4, 23 percent of the total) were treated with a preemptive reduction in FU dose, and this strategy was associated with reduced rates of FU toxicity, and no difference in response rate or other cancer outcomes [<a href="#rid108">108</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another report of 243 patients initiating fluoropyrimidine therapy, elevated plasma uracil levels &gt;16 ng/mL was associated with a 20-fold higher risk to develop grade 4 toxicity, and had a higher sensitivity than assessment for three common <em>DPYD</em> variants, but the combined use of genotyping plus phenotyping did not improve toxicity prediction [<a href="#rid109">109</a>].</p><p></p><p class="bulletIndent1">Although potentially more rapid than genotyping, these assays are not widely available, at least in the United States.</p><p></p><p class="headingAnchor" id="H204886729"><span class="h4">Management of DPD-deficient patients</span><span class="headingEndMark"> — </span>If a <em>DPYD</em> variant is identified prior to treatment, guidelines for management are available from CPIC  (<a class="graphic graphic_table graphicRef91548" href="/d/graphic/91548.html" rel="external">table 3</a>) [<a href="#rid65">65</a>]. The authors note that not all patients who harbor reduced- or no-function variants of <em>DPYD</em> manifest toxicity, and, therefore, they recommend increasing the fluoropyrimidine dose in the absence of toxicity or in patients who have subtherapeutic plasma levels. This dose increase is of particular importance for patients being treated with curative intent.</p><p>Alternative agents are needed for patients who are homozygous (ie, carrying two nonfunctional alleles). The quinazoline folate analog <a class="drug drug_general" data-topicid="10087" href="/d/drug information/10087.html" rel="external">raltitrexed</a>, which is a thymidylate synthetase inhibitor, may be a useful substitute for FU in patients with DPD deficiency [<a href="#rid111">111</a>], but it is not available in the United States. UFT is not a safe substitute for FU in this situation [<a href="#rid112">112</a>] as it is a combination of ftorafur (tegafur), an FU prodrug, plus uracil, which competes with FU for DPD.</p><p>Where available, another option is close monitoring of FU levels and pharmacokinetically guided dosing. (See  <a class="medical medical_review" href="/d/html/83810.html" rel="external">"Dosing of anticancer agents in adults", section on 'Therapeutic drug monitoring'</a>.)</p><p>Guidelines are not available from the CPIC or any other group for management of patients who are identified as having high-risk <em>TYMS</em> variants.</p><p>Most cases of DPD deficiency are diagnosed only after a severe reaction to FU. Management of these patients should include aggressive hemodynamic support, <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a>, antibiotics, hematopoietic colony stimulating factors, and, where available, <a class="drug drug_general" data-topicid="9537" href="/d/drug information/9537.html" rel="external">uridine triacetate</a> (see <a class="local">'Uridine triacetate'</a> below). Dialysis is of no benefit if renal function is normal, since even with complete DPD deficiency, FU is rapidly cleared through the urine [<a href="#rid42">42</a>]. Patients diagnosed with DPD deficiency should be advised to inform family members in case they will be treated with fluoropyrimidine chemotherapy in future.</p><p class="headingAnchor" id="H204886589"><span class="h5">Uridine triacetate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9537" href="/d/drug information/9537.html" rel="external">Uridine triacetate</a> (originally called vistonuridine) is an orally administered prodrug of uridine, a specific pharmacologic antidote to fluoropyrimidines, including FU and <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>. It is a safe and potentially life-saving treatment for overdoses of these agents. Uridine triacetate was studied in 173 adult and pediatric patients who were treated in two separate trials and had either received an overdose of FU or capecitabine (n = 147) or had early-onset, unusually severe, or rapid-onset life-threatening toxicities within 96 hours after receiving FU (n = 26, the fraction who had DPD deficiency as the cause for severe early toxicity could not be determined) [<a href="#rid113">113</a>]. Overall, 137 of 142 assessable overdose patients treated with uridine triacetate (96 percent) survived to 30 days, had rapid reversal of acute neurotoxicity or cardiotoxicity (affecting 12 patients), and either prevention of or recovery from severe mucositis or leucopenia. Among the 26 patients treated for early-onset toxicity following fluoropyrimidine therapy (some of whom presumably had DPD deficiency), 21 survived to 30 days (81 percent); all five deaths were in patients who initiated uridine triacetate beyond 96 hours after the last dose of the fluoropyrimidine. Adverse events attributable to uridine triacetate were mild and infrequent, and included diarrhea, nausea, and vomiting.</p><p>There are few data on the specific use of <a class="drug drug_general" data-topicid="9537" href="/d/drug information/9537.html" rel="external">uridine triacetate</a> in patients who develop severe fluoropyrimidine toxicity because of DPD deficiency [<a href="#rid114">114</a>]. However, the drug has been shown to prevent fatalities in mice who are treated with FU after receiving an inhibitor of DPD [<a href="#rid115">115</a>]. Thus, DPD-deficient patients who develop early severe toxicity after receiving the first dose of a fluoropyrimidine could also benefit from treatment with uridine triacetate, if the deficiency is identified soon enough after the fluoropyrimidine is administered and the drug can be obtained within 96 hours of the last dose. Uridine triacetate should not be administered for nonemergent toxicities as it may interfere with the efficacy of fluoropyrimidine treatment.</p><p><a class="drug drug_general" data-topicid="9537" href="/d/drug information/9537.html" rel="external">Uridine triacetate</a> was approved by the FDA in December 2015 for emergency use following an FU or <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> overdose, regardless of the presence of symptoms, for patients who exhibit early-onset, severe, or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (eg, GI toxicity and/or neutropenia) within 96 hours following the end of FU or capecitabine administration [<a href="#rid116">116</a>]. The dose and schedule for adults is 10 g orally every six hours for 20 doses. The dose and schedule for pediatric patients is 6.2 g/m<sup>2</sup> of body surface area orally every six hours for 20 doses. Despite its approval, uridine triacetate is not available commercially in any country. Ordering information for emergency use of uridine triacetate is available from vistogard.com.</p><p class="headingAnchor" id="H8"><span class="h3">Capecitabine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">Capecitabine</a> is a rationally designed oral fluoropyrimidine prodrug that is converted to FU in three sequential enzymatic reactions. The dose-limiting toxicities are diarrhea, palmar-plantar erythrodysesthesia, and neutropenia. Capecitabine is associated with higher rates of diarrhea compared with infusional FU regimens [<a href="#rid117">117-119</a>].</p><p>Like FU, <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> is catabolized by DPD, and there is a risk for early and severe toxicity in those who are DPD deficient. However, the specific genetic markers of capecitabine-related toxicity are less well studied than with other fluoropyrimidines, such as FU.</p><p>As with FU, routine testing for high-risk <em>DPYD</em> or <em>TYMS</em> alleles is not widely practiced prior to initiation of <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> because of the low frequency of finding a high-risk allele and the fact that patients who lack a high-risk variant may still suffer grade 3 or 4 FU-related toxicity. Nevertheless, testing is appropriate for patients who develop early severe toxicity (neutropenia, mucositis, diarrhea, neurotoxicity, and/or cardiotoxicity). (See <a class="local">'DPD deficiency'</a> above.)</p><p>To avoid the risk of severe and potentially fatal reactions, the United States prescribing information for <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> recommends to withhold or permanently discontinue the drug in patients with evidence of acute early-onset or unusually severe toxicity, which may indicate a near-complete or total absence of DPD activity [<a href="#rid120">120</a>]. Furthermore, it states that no capecitabine dose has been proven safe for patients with complete absence of DPD activity and that there are insufficient data to recommend a specific dose in patients with partial DPD activity as measured by any specific test. However, it stops short of recommending preemptive testing for all patients prior to initiating therapy.</p><p><a class="drug drug_general" data-topicid="9537" href="/d/drug information/9537.html" rel="external">Uridine triacetate</a> is approved for emergency use in cases of <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> overdose or early-onset, severe, or life-threatening toxicity, such as might occur in a DPD-deficient patient. (See <a class="local">'Uridine triacetate'</a> above.)</p><p class="headingAnchor" id="H204890821"><span class="h4">Dosing</span><span class="headingEndMark"> — </span>There appear to be large regional differences in the tolerance to <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> and other fluoropyrimidines [<a href="#rid97">97</a>]. These differences might, in part, be based on population-specific pharmacogenomic variability (eg, Asian patients seem to tolerate fluoropyrimidines better than non-Asian patients, and although not studied according to ethnicity, genetic factors that are associated with capecitabine sensitivity, such as SNPs, have been identified [<a href="#rid121">121</a>]). However, differences in lifestyle and diet (eg, dietary folate intake) could also contribute.</p><p>Because of these issues, the optimal dose of <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>, particularly for American patients, remains undefined. The initially approved dose for treatment of metastatic breast and colorectal cancer was 2500 mg/m<sup>2</sup> per day for 14 of every 21 days, but later studies suggest that this dose is too high, particularly in American patients. Lower doses (beginning at 2000 mg per day for 14 of every 21 days) may improve the therapeutic index without compromising efficacy. An alternative capecitabine dosing schedule as has been used in women with breast cancer (2000 mg total dose in two divided doses for seven days on, seven days off) may be associated with less diarrhea [<a href="#rid122">122,123</a>]. (See  <a class="medical medical_review" href="/d/html/83848.html" rel="external">"Endocrine therapy resistant, hormone receptor-positive, HER2-negative advanced breast cancer", section on 'Capecitabine'</a> and  <a class="medical medical_review" href="/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Oral fluoropyrimidines'</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">Ftorafur</span><span class="headingEndMark"> — </span>Two oral formulations of ftorafur (tegafur), a FU prodrug, have been developed and are in use in Japan; neither drug is available in the United States.</p><p class="bulletIndent1"><span class="glyph">●</span>UFT is a combination of ftorafur with uracil, which has been in widespread use in Japan for over 20 years. UFT is currently not available in the United States. Uracil competitively inhibits the enzyme DPD, leading to higher intratumoral concentrations of FU.</p><p></p><p class="bulletIndent1">Grade 3 or 4 diarrhea is seen in up to 12 percent of patients treated with single-agent UFT and in 8 to 20 percent of those in whom UFT was given with LV [<a href="#rid124">124,125</a>]. Prompt discontinuation of UFT at the onset of diarrhea usually prevents severe GI toxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>S-1 is an oral fluoropyrimidine that includes three different agents: ftorafur, gimeracil (5-chloro-2,4 dihydropyridine, a potent inhibitor of DPD), and oteracil (potassium oxonate, which inhibits phosphorylation of intestinal FU, thought responsible for treatment-related diarrhea).</p><p></p><p class="bulletIndent1">In animal models, potassium oxonate is protective against FU-induced diarrhea [<a href="#rid126">126,127</a>]. In a randomized phase III trial of surgery followed by one year of S-1 versus surgery alone in gastric cancer, the incidence of grade 3 or 4 diarrhea was only 3.1 percent with S-1 [<a href="#rid128">128</a>]. However, in a randomized trial of S-1 versus <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> as adjuvant therapy for colon cancer, grade 3 or 4 diarrhea occurred more commonly with S-1 than capecitabine (8 versus 2 percent) [<a href="#rid129">129</a>]. Randomized controlled trials of S-1 with <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> compared with FOLFOX or CAPOX have found a higher incidence of severe diarrhea in the S-1 arm compared with standard therapy [<a href="#rid130">130,131</a>].</p><p></p><p class="headingAnchor" id="H10"><span class="h3">Irinotecan</span><span class="headingEndMark"> — </span>There are two types of diarrhea associated with <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>:</p><p class="bulletIndent1"><span class="glyph">●</span>Early-onset diarrhea with <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> occurs during or within several hours of drug infusion in 45 to 50 percent of patients and is cholinergically mediated (ie, related to increased motility) [<a href="#rid15">15</a>]. It is often accompanied by other symptoms of cholinergic excess, including abdominal cramping, rhinitis, lacrimation, and salivation. The mean duration of symptoms is 30 minutes; it is usually well controlled by subcutaneous or IV <a class="drug drug_general" data-topicid="8983" href="/d/drug information/8983.html" rel="external">atropine</a>. (See <a class="local">'Pathogenesis/mechanisms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By contrast, late irinotecan-associated diarrhea is not cholinergically mediated. The pathophysiology of late diarrhea appears to be multifactorial, with contributions from dysmotility and secretory factors, as well as a direct toxic effect on the intestinal mucosa [<a href="#rid132">132,133</a>].</p><p></p><p class="bulletIndent1">Late diarrhea from <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> is unpredictable, noncumulative, and occurs at all dose levels. In early clinical trials of irinotecan, late diarrhea and neutropenia were the main dose-limiting toxicities [<a href="#rid134">134,135</a>]. Diarrhea of any grade was seen in 50 to 88 percent of patients, and it was severe in 9 to 31 percent. Diarrhea has been less common in later studies because of the stricter adherence to management guidelines (including routine early institution of high-dose <a class="drug drug_general" data-topicid="9571" href="/d/drug information/9571.html" rel="external">loperamide</a>) and the use of infusional rather than bolus FU in combination with irinotecan. (See  <a class="medical medical_review" href="/d/html/98342.html" rel="external">"Management of acute chemotherapy-related diarrhea", section on 'Loperamide and diphenoxylate-atropine'</a>.)</p><p></p><p>The median time to onset is approximately six days with the 350 mg/m<sup>2</sup> every-three-week schedule and 11 days with the weekly schedule (125 mg/m<sup>2</sup>) [<a href="#rid133">133,136</a>]. Late diarrhea is less common with the every-three-week schedule. In a randomized trial comparing the two administration schedules of single-agent <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>, the incidence of severe diarrhea was significantly less with the every-three-week schedule (19 versus 36 percent for weekly therapy) [<a href="#rid137">137</a>]. However, the incidence of cholinergic symptoms was significantly lower with weekly therapy (31 versus 61 percent). In some studies, older age, low performance status, and prior pelvic radiation were found to be predisposing factors [<a href="#rid133">133</a>]. For unclear reasons, diarrhea is more common in White patients than in Black patients receiving irinotecan-based therapy [<a href="#rid138">138</a>].</p><p><a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">Irinotecan</a> produces mucosal changes associated with apoptosis, such as epithelial vacuolization, and goblet cell hyperplasia, suggestive of mucin hypersecretion [<a href="#rid3">3</a>]. These changes appear related to the accumulation of the active metabolite of irinotecan, SN-38, in the intestinal mucosa [<a href="#rid6">6</a>].</p><p>SN-38 is glucuronidated in the liver and is then excreted in the bile. The conjugated metabolite SN-38G does not appear to cause diarrhea. However, SN-38G can be deconjugated in the intestine by beta-glucuronidase present in intestinal bacteria. A direct correlation has been noted between mucosal damage and either low glucuronidation rates or increased intestinal beta-glucuronidase activity [<a href="#rid139">139-141</a>]. Severe toxicity has been described with <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> in patients with Gilbert syndrome who have defective hepatic glucuronidation [<a href="#rid140">140</a>]. (See  <a class="medical medical_review" href="/d/html/3578.html" rel="external">"Gilbert syndrome"</a> and  <a class="medical medical_review" href="/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Treatment-related toxicity'</a>.)</p><p>Common genetic polymorphisms of the UDP-glucuronyltransferase (<em>UGT</em>) gene can affect the metabolism of <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>. The possible impact of genetic variability on the toxicity of irinotecan is discussed below. (See <a class="local">'Irinotecan plus FU'</a> below.)</p><p class="headingAnchor" id="H11"><span class="h4">UGT1A1 polymorphisms</span><span class="headingEndMark"> — </span>Preemptive testing for the uridine diphospho-glucuronosyltransferase 1A1 (<em>UGT1A1)</em> genotypes that are associated with a poor metabolizer phenotype prior to initiating <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> is a controversial and evolving area, and experts differ. Although many institutions do not routinely screen patients, at our institution preemptive testing is recommended for all individuals initiating irinotecan, and we reduce initial starting doses by approximately 30 percent if a high-risk genotype is identified.</p><p>SN-38 is further metabolized by the polymorphic enzyme <em>UGT1A1</em>. Individuals who inherit certain polymorphisms in the <em>UGT1A1</em> gene or its promoter have reduced enzymatic activity and they are referred to as having a "poor metabolizer" phenotype because of decreased clearance of SN-38, which increases the risk for severe irinotecan-related neutropenia and, to a lesser degree, diarrhea. Most of the reported data describing the excess toxicity experienced by these individuals are in those carrying one or more *28 alleles, which is the most frequent alteration in European and African ancestries [<a href="#rid142">142</a>]. The *6 polymorphism is also associated with <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> toxicity and is more common in East Asian ancestry than in European or African ancestry. The *93 polymorphism is associated with increased SN-38 exposure and irinotecan toxicity and is common in African and European ancestries but less common in East Asian ancestry  (<a class="graphic graphic_table graphicRef134942" href="/d/graphic/134942.html" rel="external">table 4</a>) [<a href="#rid142">142,143</a>]. In general, patients carrying two alleles (eg, homozygotes with *28/*28, *6/*6, or *6/*28) conferring decreased expression of function are at a higher risk for severe toxicity, compared with those carrying one allele (eg, *1/*28).</p><p>Some poor metabolizers may be identified because they have Gilbert's syndrome, an inherited deficiency in <em>UGT1A1</em> enzyme activity caused by polymorphisms in the <em>UGT1A1 </em>gene (typically the *28 allele), and characterized by increased unconjugated bilirubin in the blood, which is usually asymptomatic. Otherwise, the identification of individuals who have a poor metabolizer phenotype requires genetic testing for high-risk alleles. In one study of 1500 patients undergoing routine genotyping at a single institution, 17 percent were found to have a <em>UGT1A1</em> genotype that would result in a poor metabolizer phenotype (*6/*6, *28/*28, *6/*28) [<a href="#rid106">106</a>].</p><p>The United States Prescribing Information for <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> specifies that individuals who are homozygous for the <em>UGT1A1 </em>*28 or *6 allele and compound heterozygotes (*6/*28) are at risk for severe irinotecan toxicity (mainly neutropenia) and both pre-emptive testing for these <em>UGT1A1</em> high-risk genotypes and a reduced initial dose of irinotecan in poor metabolizers should be "considered" [<a href="#rid120">120</a>]. However, whether preemptive testing for <em>UGT1A1</em> genotype should be carried out in all individuals prior to receiving irinotecan is a controversial, evolving area, and experts differ. Some, including our institution, screen all patients. However, others do not. Preemptive testing is not widely recommended in various oncology guidelines.</p><p>This subject is addressed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/83810.html" rel="external">"Dosing of anticancer agents in adults", section on 'UGT1A1 polymorphisms and irinotecan'</a>.)</p><p class="headingAnchor" id="H12"><span class="h4">Irinotecan plus FU</span><span class="headingEndMark"> — </span>A standard regimen for treatment of metastatic colorectal cancer is the combination of <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>, FU, and LV [<a href="#rid144">144,145</a>]. Both irinotecan and FU have overlapping toxicity profiles; a major concern with early studies of this triplet regimen was the potential for enhanced GI toxicity. The spectrum of GI toxicity with combined irinotecan plus FU and LV is schedule dependent:</p><p class="headingAnchor" id="H717960378"><span class="h5">IFL</span><span class="headingEndMark"> — </span>In two early trials of bolus <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> plus weekly FU and LV (the IFL regimen), unacceptably high rates of early treatment-related mortality were noted [<a href="#rid146">146-148</a>]. In both trials, patients receiving irinotecan plus bolus FU and LV (either daily or weekly) had a threefold higher rate of treatment-related death than those enrolled on other arms [<a href="#rid146">146</a>]. Most of the early deaths appeared to be due to a cluster of mainly GI symptoms that included diarrhea, nausea, vomiting, and abdominal cramping, which was typically accompanied by dehydration, neutropenia, fever, and electrolyte abnormalities [<a href="#rid147">147</a>].</p><p>Use of this regimen is no longer recommended, largely because of the risk of diarrhea and neutropenia.</p><p class="headingAnchor" id="H717960451"><span class="h5">FOLFIRI</span><span class="headingEndMark"> — </span>GI toxicity is less severe with other irinotecan-containing regimens that utilize <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> plus LV and short-term infusional FU (eg, FOLFIRI). In at least four trials, rates of grade 3 or 4 diarrhea with FOLFIRI (every-other-week irinotecan plus short-term infusional FU and LV) were between 10 and 14 percent [<a href="#rid117">117,145,149,150</a>].</p><p>The better tolerability of regimens in which <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> is combined with infusional rather than bolus FU [<a href="#rid117">117</a>] has led to the widespread use of FOLFIRI rather than IFL. (See  <a class="medical medical_review" href="/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Irinotecan regimens'</a>.)</p><p class="headingAnchor" id="H168201052"><span class="h5">Liposomal irinotecan plus fluorouracil and leucovorin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="104962" href="/d/drug information/104962.html" rel="external">Liposomal irinotecan</a> is a nanoliposomal encapsulated preparation that allows <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> to remain in circulation for a longer duration compared with standard irinotecan; this increases drug uptake within tumor cells and conversion of irinotecan to its active form, SN-38 [<a href="#rid151">151</a>]. Liposomal irinotecan is approved in combination with FU/LV for second-line treatment of gemcitabine-refractory metastatic pancreatic cancer based on results from the international phase III NAPOLI-1 trial [<a href="#rid152">152</a>]. Severe diarrhea, which can be of early-onset or late-onset type, occurred in 13 percent of those receiving combination therapy in this trial.</p><p>As with nonencapsulated <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>, the manufacturer of <a class="drug drug_general" data-topicid="104962" href="/d/drug information/104962.html" rel="external">liposomal irinotecan</a> recommends that the starting dose be lowered (from 70 to 50 mg/m<sup>2</sup> every two weeks) in patients homozygous for <em>UGT1A1</em>*28 [<a href="#rid120">120</a>]. However, it does not specifically recommend testing for the <em>UGT1A1</em>*28 variant prior to starting therapy. (See  <a class="medical medical_review" href="/d/html/127094.html" rel="external">"Second-line systemic therapy for advanced exocrine pancreatic cancer", section on 'Liposomal irinotecan'</a>.)</p><p class="headingAnchor" id="H2768024113"><span class="h4">Irinotecan plus capecitabine</span><span class="headingEndMark"> — </span>Several studies of <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> plus <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> compared with FOLFIRI as treatment of metastatic colorectal cancer have demonstrated high rates GI toxicity [<a href="#rid117">117,153</a>]. The irinotecan doses were 240-250 mg/m<sup>2</sup> every 21 days. A more favorable toxicity profile was noted in a phase III randomized trial of XELIRI versus FOLFIRI used a lower irinotecan dose of 200 mg/m<sup>2</sup> every 21 days and lower capecitabine dose of 800 mg/m<sup>2</sup> twice daily on days 1 through 14, every 21 days [<a href="#rid154">154</a>].</p><p class="headingAnchor" id="H14"><span class="h3">Oxaliplatin combinations</span><span class="headingEndMark"> — </span>Combinations of <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> plus FU and LV have become the most widely chosen first-line chemotherapy regimens for metastatic colorectal cancer, at least in North America. In addition, oxaliplatin-containing regimens have also been shown to provide a survival benefit over non-oxaliplatin-containing regimens for adjuvant therapy of stage III colon cancer. (See  <a class="medical medical_review" href="/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'FOLFOX versus FOLFIRI'</a> and  <a class="medical medical_review" href="/d/html/2471.html" rel="external">"Adjuvant therapy for resected stage III (node-positive) colon cancer", section on 'Oxaliplatin-based therapy'</a>.)</p><p>Enterotoxicity with combined <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> and FU-containing chemotherapy is dependent on the schedule of FU administration. With oxaliplatin combined with short-term infusional FU (a regimen referred to as FOLFOX), rates of grade 3 or 4 diarrhea are less than 20 percent [<a href="#rid155">155-158</a>]. On the other hand, enterotoxicity is much more frequent and severe with regimens that combine oxaliplatin with weekly bolus FU and LV (eg, FLOX) [<a href="#rid39">39</a>], especially those that include daily bolus FU and LV [<a href="#rid148">148</a>].</p><p>This was shown in the NSABP C-07 trial, a comparison of the Roswell park regimen without or with (ie, FLOX) <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> as adjuvant therapy for stage II or III colon cancer [<a href="#rid39">39</a>]. During therapy, 79 of 1857 patients (4.3 percent) developed a syndrome of bowel wall injury characterized by hospitalization for management of severe diarrhea or dehydration and radiographic or endoscopic evidence of bowel wall thickening or ulceration, and the incidence was significantly higher in patients assigned to FLOX as compared with FU/LV (5.5 versus 3 percent). The incidence of bowel wall injury during chemotherapy was particularly high with FLOX as compared with FU and LV in patients aged 60 or older (6.7 versus 2.9 percent) and in females (9.1 versus 3.9 percent).</p><p>Enteric sepsis, characterized by grade 3 or worse diarrhea and grade 4 neutropenia (with or without bacteremia), occurred in 22 patients on FLOX and 8 patients on FU/LV. There were five deaths due to enteropathy, all in patients with enteric sepsis, with or without bowel wall injury. These results underscore the need to closely monitor patients treated with adjuvant FU/LV chemotherapy for diarrhea and provide aggressive management of this symptom complex, particularly if <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> has been added.</p><p class="headingAnchor" id="H1409188872"><span class="h4">Capecitabine plus oxaliplatin</span><span class="headingEndMark"> — </span>The combination of <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> and <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> (XELOX, also called CAPOX) has also been intensely investigated given its convenience. A phase III comparison of XELOX (capecitabine at 1000 mg/m<sup>2</sup> twice a day for 14 days plus oxaliplatin 130 mg/m<sup>2</sup> on day 1 every three weeks) versus FOLFOX (continuous infusion of FU at 2250 mg/m<sup>2</sup> over 48 hours on days 1, 8, 15, 22, 29, and 36 plus oxaliplatin 85 mg/m<sup>2</sup> on days 1, 15, and 29 every six weeks) in patients with metastatic colorectal cancer reported a significantly lower rate of grade 3 or 4 diarrhea with XELOX (14 versus 24 percent) but a significantly higher rate of grade 1 or 2 hyperbilirubinemia (37 versus 21 percent) [<a href="#rid159">159</a>].</p><p>The largest amount of safety data for XELOX comes from the IDEA collaboration, an international study that compared three versus six months of adjuvant chemotherapy [<a href="#rid160">160</a>]. The six trials included in the IDEA collaboration included 5071 patients who received XELOX, 2554 for three months and 2517 for six months. As expected, rates of grade 3 or worse diarrhea were higher in patients receiving six months of XELOX versus three months (21.5 versus 17.2 percent), but rates of diarrhea were similar for patients receiving XELOX versus <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> plus short-term infusional FU (FOLFOX). (See  <a class="medical medical_review" href="/d/html/2471.html" rel="external">"Adjuvant therapy for resected stage III (node-positive) colon cancer", section on 'Duration of therapy'</a>.)</p><p class="headingAnchor" id="H3139057448"><span class="h3">Fluoropyrimidine, irinotecan and oxaliplatin combinations</span><span class="headingEndMark"> — </span>Combinations of leucovorin-modulated FU, plus <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>, and <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> (FOLFIRINOX, FOLFOXIRI) have increased rates of diarrhea compared with two-drug chemotherapy regimens such as FOLFOX or FOLFIRI, but they have become the standard of care for many patients with pancreatic cancer and select patients with colorectal cancer due to their superior efficacy and survival data.</p><p class="bulletIndent1"><span class="glyph">●</span>The ACCORD 11 trial, a randomized comparison of the FOLFIRINOX regimen  (<a class="graphic graphic_table graphicRef79571" href="/d/graphic/79571.html" rel="external">table 5</a>) against <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> in metastatic pancreatic cancer, showed that 21 of 165 patients (12.7 percent) experienced grade 3 or worse diarrhea compared with 3 of 169 patients (1.8 percent) receiving gemcitabine alone [<a href="#rid161">161</a>]. (See  <a class="medical medical_review" href="/d/html/2475.html" rel="external">"Initial systemic chemotherapy for metastatic exocrine pancreatic cancer", section on 'FOLFOX and FOLFIRINOX'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similarly, in a study of modified FOLFIRINOX  (<a class="graphic graphic_table graphicRef109546" href="/d/graphic/109546.html" rel="external">table 6</a>) as adjuvant therapy for pancreatic cancer, 47 of 238 patients (20 percent) experienced grade 3 or higher diarrhea, and 200 of 238 patients (84.4 percent) experienced diarrhea of any grade [<a href="#rid162">162</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A related regimen, FOLFOXIRI in combination with <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>  (<a class="graphic graphic_table graphicRef127023" href="/d/graphic/127023.html" rel="external">table 7</a>) has been compared with both FOLFOX/bevacizumab and FOLFIRI/bevacizumab in metastatic colorectal cancer (see  <a class="medical medical_review" href="/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Three- versus two-drug combinations'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The TRIBE study showed that 47 of 250 patients (18.8 percent) who received FOLFOXIRI/<a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> experienced grade 3 or higher diarrhea, which was significantly higher than 27 of 254 patients (10.6 percent) who received FOLFIRI/bevacizumab [<a href="#rid163">163</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The TRIBE 2 study comparing FOLFOXIRI/<a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> with FOLFOX/bevacizumab also showed higher rates of grade 1 or 2 diarrhea (50.3 versus 35.1 percent) and grade 3 or higher diarrhea (17.0 versus 5.4 percent) with the four-drug regimen [<a href="#rid164">164</a>].</p><p></p><p class="headingAnchor" id="H16"><span class="h3">Pemetrexed</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">Pemetrexed</a> is an antifolate with activity in NSCLC and mesothelioma. In phase II and III trials of pemetrexed monotherapy, diarrhea (typically grade 1 or 2) has been reported in approximately 10 to 15 percent of patients [<a href="#rid165">165-167</a>]. Pemetrexed in combination with platinum chemotherapy is widely used as treatment for NSCLC. Severe diarrhea is rare with pemetrexed/platinum regimens [<a href="#rid168">168-170</a>]. (See  <a class="medical medical_review" href="/d/html/4629.html" rel="external">"Subsequent line therapy in non-small cell lung cancer lacking a driver mutation"</a> and  <a class="medical medical_review" href="/d/html/4609.html" rel="external">"Systemic treatment for unresectable malignant pleural mesothelioma"</a>.)</p><p class="headingAnchor" id="H3597507"><span class="h3">Cabazitaxel</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="15577" href="/d/drug information/15577.html" rel="external">Cabazitaxel</a> is a semisynthetic taxane that is approved for the treatment of advanced prostate cancer. Diarrhea is a frequent problem, developing in 15 to 50 percent of treated patients, but it is severe (grade 3 or 4) in only 1 to 6 percent [<a href="#rid171">171-174</a>]. Nevertheless, in a pivotal phase III trial conducted in men with advanced prostate cancer, some deaths occurred in men treated with cabazitaxel that were attributed to diarrhea and electrolyte imbalance [<a href="#rid173">173</a>]. A later study that established the noninferiority of a 20 mg/m<sup>2</sup> dose compared with the standard 25 mg/m<sup>2</sup> dose showed that diarrhea rates and severity may be dose dependent. While the greatest improvement was in rates of neutropenia (41.8 versus 73.3 percent) and febrile neutropenia (2.1 versus 9.2 percent, the rates of diarrhea of any grade (30.7 versus 39.8 percent) and of grade 3 or higher diarrhea (1.4 versus 4.0 percent) were also modestly improved [<a href="#rid175">175</a>]. (See  <a class="medical medical_review" href="/d/html/6945.html" rel="external">"Chemotherapy in advanced castration-resistant prostate cancer", section on 'Men who have received prior docetaxel'</a>.)</p><p class="headingAnchor" id="H3377728716"><span class="h3">Other taxanes</span><span class="headingEndMark"> — </span>Diarrhea is commonly reported in studies of the other taxanes such as <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>, <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> and nanoparticle albumin-bound (nab)-paclitaxel. In studies of docetaxel used for castration-resistant prostate cancer, diarrhea occurred in approximately 35 percent of patients but was grade 3 or higher in less than 3 percent [<a href="#rid176">176,177</a>]. Rates and severity of diarrhea are similar with paclitaxel and <a class="drug drug_general" data-topicid="10159" href="/d/drug information/10159.html" rel="external">nabpaclitaxel</a> compared with docetaxel [<a href="#rid178">178,179</a>]. For example, in the Impassion130 trial comparing nabpaclitaxel plus <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> versus nabpaclitaxel alone, approximately 33 percent of patients experienced diarrhea of any grade, and less than 3 percent experienced grade 3 or higher diarrhea in both study arms [<a href="#rid178">178</a>].</p><p>Predictably, combining taxanes with other chemotherapeutic agents can increase both the frequency and severity of diarrhea. For example, in a study of perioperative chemotherapy for gastric cancer, the regimen of FU/LV, <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> and <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> (FLOT) caused significantly more diarrhea than the epirubicin-containing regimens (52 versus 29 percent for grade 1 or 2 and 10 percent versus 4 percent for grade 3 or 4, p = 0.0016) [<a href="#rid180">180</a>].</p><p class="headingAnchor" id="H204887561"><span class="h3">Bortezomib and other proteasome inhibitors</span><span class="headingEndMark"> — </span>Diarrhea is commonly seen with <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>, a proteasome inhibitor used in the treatment of multiple myeloma [<a href="#rid181">181</a>]. In the pivotal studies with this agent, diarrhea occurred in 51 percent of patients, with 8 percent of the events being grade 3 or 4. (See  <a class="medical medical_review" href="/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies", section on 'Proteasome inhibitors'</a> and  <a class="medical medical_review" href="/d/html/121127.html" rel="external">"Multiple myeloma: Treatment of first or second relapse", section on 'Daratumumab, bortezomib, dexamethasone (DVd)'</a>.)</p><p>Diarrhea is less common and less severe with <a class="drug drug_general" data-topicid="86042" href="/d/drug information/86042.html" rel="external">carfilzomib</a> [<a href="#rid182">182</a>] and the orally active agent <a class="drug drug_general" data-topicid="105607" href="/d/drug information/105607.html" rel="external">ixazomib</a> [<a href="#rid183">183</a>].</p><p class="headingAnchor" id="H204887568"><span class="h3">Vorinostat and belinostat</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9491" href="/d/drug information/9491.html" rel="external">Vorinostat</a>, a histone deacetylase inhibitor, was approved by the FDA in 2006 for the management of cutaneous T-cell lymphoma. In the pivotal studies of this agent, diarrhea was observed in 52 percent of the patients, with the great majority of these episodes being grade 1 or 2 events controllable by oral agents [<a href="#rid184">184</a>].</p><p><a class="drug drug_general" data-topicid="96188" href="/d/drug information/96188.html" rel="external">Belinostat</a> is another histone deacetylase inhibitor that is approved for treatment of peripheral T-cell lymphoma. In an initial study, diarrhea was reported in 23 percent of treated patients but was severe in only 2 percent [<a href="#rid185">185</a>].</p><p class="headingAnchor" id="H889440149"><span class="h3">Lenalidomide and other immunomodulatory imide (IMiD) drugs</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">Lenalidomide</a> can cause constipation or diarrhea. <a class="drug drug_general" data-topicid="88099" href="/d/drug information/88099.html" rel="external">Pomalidomide</a> can also cause both constipation or diarrhea in up to one-third of patients. Among patients with diarrhea, bile salt malabsorption may be one potential etiology that responds to treatment including reduced fat intake and bile acid sequestrants [<a href="#rid186">186</a>].</p><p class="headingAnchor" id="H17"><span class="h2">Risk with molecularly targeted agents</span><span class="headingEndMark"> — </span>Diarrhea is a common side effect of several molecularly targeted agents.</p><p class="headingAnchor" id="H18"><span class="h3">Small molecule EGFR inhibitors</span><span class="headingEndMark"> — </span>Diarrhea is common in patients receiving small molecule epidermal growth factor receptor (EGFR) TKIs, such as <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a>, <a class="drug drug_general" data-topicid="8712" href="/d/drug information/8712.html" rel="external">gefitinib</a>, <a class="drug drug_general" data-topicid="90144" href="/d/drug information/90144.html" rel="external">afatinib</a>, <a class="drug drug_general" data-topicid="119171" href="/d/drug information/119171.html" rel="external">dacomitinib</a>, <a class="drug drug_general" data-topicid="105441" href="/d/drug information/105441.html" rel="external">osimertinib</a>, and <a class="drug drug_general" data-topicid="132715" href="/d/drug information/132715.html" rel="external">mobocertinib</a> [<a href="#rid169">169,187-190</a>]. For patients treated with gefitinib and erlotinib, diarrhea is most likely to occur within the first four weeks of treatment initiation; with afatinib, diarrhea is most likely to occur within the first seven days. Although diarrhea is reported in up to 90 percent of patients treated with any of these agents (especially those treated with afatinib [<a href="#rid191">191</a>] and mobocertinib [<a href="#rid192">192</a>]), it is severe in fewer than 20 percent and typically can be easily managed by the use of <a class="drug drug_general" data-topicid="9571" href="/d/drug information/9571.html" rel="external">loperamide</a>. Uncommonly, diarrhea necessitates dose reduction or treatment interruptions. Although diarrhea can have a profound effect on patients, the available evidence suggests that diarrhea may be a surrogate indicator of antitumor efficacy [<a href="#rid193">193,194</a>].</p><p>Synergistic toxicity may be a problem when these agents are combined with chemotherapy. Diarrhea has been a significant dose-limiting toxicity in a number of studies combining EGFR inhibitors with concurrent radiation and chemotherapy [<a href="#rid195">195,196</a>].</p><p class="headingAnchor" id="H1223021529"><span class="h3">Anti-EGFR monoclonal antibodies</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">Cetuximab</a> is a chimeric immunoglobulin G subclass 1 (IgG1) monoclonal antibody that binds to the extracellular domain of the epidermal growth factor receptor (EGFR), competitively inhibiting ligand binding. In contrast with small-molecule EGFR inhibitors, cetuximab-related diarrhea is generally not severe:</p><p class="bulletIndent1"><span class="glyph">●</span>A phase II study of <a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a> as monotherapy for 346 patients with metastatic colorectal cancer reported diarrhea of any grade in 12.7 percent [<a href="#rid197">197</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When toxicities were reported, regardless of attribution to treatment, in a phase II study of patients with lung cancer treated with <a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a> alone, 22.7 percent had diarrhea of any grade [<a href="#rid198">198</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rates of grade 3 or 4 diarrhea in studies of single-agent <a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a> are only 1.5 to 2 percent [<a href="#rid197">197-201</a>].</p><p></p><p><a class="drug drug_general" data-topicid="10336" href="/d/drug information/10336.html" rel="external">Panitumumab</a> is a fully human IgG2 monoclonal antibody directed against the EGFR. A phase III comparison of best supportive care (BSC) with or without panitumumab reported diarrhea of any grade in 21 percent of patients receiving panitumumab (grade 3, 1 percent), compared with 11 percent with BSC alone (none grade 3) [<a href="#rid202">202</a>]. Similar results are reported by others with panitumumab monotherapy [<a href="#rid203">203</a>].</p><p class="headingAnchor" id="H3593490664"><span class="h3">PI3K inhibitors</span><span class="headingEndMark"> — </span>Phosphoinositide 3-kinase (PI3K) inhibitors (eg, <a class="drug drug_general" data-topicid="96416" href="/d/drug information/96416.html" rel="external">idelalisib</a>, <a class="drug drug_general" data-topicid="119167" href="/d/drug information/119167.html" rel="external">duvelisib</a>, and <a class="drug drug_general" data-topicid="121400" href="/d/drug information/121400.html" rel="external">alpelisib</a>) are all associated with diarrhea, which can be severe.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idelalisib</strong> – <a class="drug drug_general" data-topicid="96416" href="/d/drug information/96416.html" rel="external">Idelalisib</a> is an oral inhibitor of PI3K delta; it is approved for treatment of relapsed chronic lymphocytic leukemia, follicular lymphoma, and small lymphocytic lymphoma. (See  <a class="medical medical_review" href="/d/html/4520.html" rel="external">"Treatment of relapsed or refractory chronic lymphocytic leukemia", section on 'Idelalisib'</a>.)</p><p></p><p class="bulletIndent1">Across clinical trials, approximately 14 percent of treated patients have developed severe diarrhea or colitis (grade 3 or worse) [<a href="#rid204">204-206</a>]. Diarrhea can occur at any time during treatment, and it responds poorly to antimotility agents. Following interruption of therapy and, in some cases, the use of glucocorticoids or <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a> [<a href="#rid205">205</a>], the median time to resolution is between one and four weeks. Some patients with moderate to severe diarrhea have developed serious and fatal intestinal perforation. (See <a class="local">'Idelalisib'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duvelisib</strong> – <a class="drug drug_general" data-topicid="119167" href="/d/drug information/119167.html" rel="external">Duvelisib</a> is an oral dual inhibitor of PI3K delta and gamma that is approved for treatment of chronic lymphocytic leukemia. (See  <a class="medical medical_review" href="/d/html/4520.html" rel="external">"Treatment of relapsed or refractory chronic lymphocytic leukemia"</a>.)</p><p></p><p class="bulletIndent1">Serious (grade ≥3), including fatal, diarrhea or colitis has been reported in 11 to 23 percent of patients treated with <a class="drug drug_general" data-topicid="119167" href="/d/drug information/119167.html" rel="external">duvelisib</a> [<a href="#rid207">207-209</a>]. The United States Prescribing Information recommends withholding the drug for moderate (grade 1 or 2) diarrhea that is unresponsive to antidiarrheal agents and for those with abdominal pain, stool with mucus or blood, peritoneal signs, or grade 3 diarrhea [<a href="#rid120">120</a>]. Supportive therapy should be initiated with enteric-acting glucocorticoids (eg, <a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">budesonide</a>), or systemic glucocorticoids if there is abdominal pain, peritoneal signs, stool with mucous or blood, or grade 3 diarrhea.</p><p></p><p>Both <a class="drug drug_general" data-topicid="96416" href="/d/drug information/96416.html" rel="external">idelalisib</a> and <a class="drug drug_general" data-topicid="119167" href="/d/drug information/119167.html" rel="external">duvelisib</a> carry boxed warnings from the FDA for diarrhea and colitis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alpelisib</strong> – <a class="drug drug_general" data-topicid="121400" href="/d/drug information/121400.html" rel="external">Alpelisib</a> is another inhibitor of PI3K alpha that is approved, in combination with <a class="drug drug_general" data-topicid="8784" href="/d/drug information/8784.html" rel="external">fulvestrant</a>, for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancers that have a mutation in the catalytic alpha subunit of PI3K.</p><p></p><p class="bulletIndent1">Diarrhea is common and occurs in approximately 60 percent of treated patients; it is severe (grade 3) in approximately 7 percent [<a href="#rid210">210</a>]. Specific recommendations for treatment interruption/dose reduction in the event of diarrhea are outlined in the table  (<a class="graphic graphic_table graphicRef132331" href="/d/graphic/132331.html" rel="external">table 8</a>).</p><p></p><p class="headingAnchor" id="H19"><span class="h3">Small molecule inhibitors of VEGFR</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">Sorafenib</a>, <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="17141" href="/d/drug information/17141.html" rel="external">axitinib</a>, <a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">regorafenib</a>, <a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">pazopanib</a>, <a class="drug drug_general" data-topicid="87299" href="/d/drug information/87299.html" rel="external">cabozantinib</a>, <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a>, and <a class="drug drug_general" data-topicid="16484" href="/d/drug information/16484.html" rel="external">vandetanib</a> are orally active inhibitors of multiple tyrosine kinases including the vascular endothelial growth factor receptor (VEGFR). Diarrhea is a prominent side effect of all VEGFR inhibitors. In clinical trials, diarrhea of any grade has been reported in 30 to 79 percent of patients (highest rates with vandetanib), with severe diarrhea (grade 3 or 4) in 3 to 17 percent [<a href="#rid211">211-217</a>]. (See  <a class="medical medical_review" href="/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Gastrointestinal toxicities'</a>.)</p><p class="headingAnchor" id="H21"><span class="h3">BCR-ABL1 and KIT tyrosine kinase inhibitors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">Imatinib</a>, an inhibitor of BCR-ABL1 and other tyrosine kinases, such as KIT, causes diarrhea in approximately 30 percent of patients, but severe diarrhea is rare [<a href="#rid218">218</a>]. Similarly, <a class="drug drug_general" data-topicid="8852" href="/d/drug information/8852.html" rel="external">dasatinib</a>, which targets BCR-ABL1, KIT, and the Src family of tyrosine kinases (among others), causes diarrhea in approximately 30 percent, which is severe in &lt;5 percent. Hemorrhagic colitis is also reported in patients treated with dasatinib, although the frequency with which this occurs is not established [<a href="#rid219">219</a>]. <a class="drug drug_general" data-topicid="9448" href="/d/drug information/9448.html" rel="external">Nilotinib</a>, an inhibitor of BCR-ABL1, KIT, and PDGFR is also associated with diarrhea in 19 to 28 percent of patients, which is usually not severe [<a href="#rid220">220</a>].</p><p>Similarly, diarrhea is reported in 28 percent of patients treated with the KIT/PDGFRA inhibitor <a class="drug drug_general" data-topicid="128227" href="/d/drug information/128227.html" rel="external">ripretinib</a>, but it is severe in only 1 percent [<a href="#rid221">221</a>].</p><p>On the other hand, <a class="drug drug_general" data-topicid="86371" href="/d/drug information/86371.html" rel="external">bosutinib</a>, an inhibitor of BCR-ABL1 and the Src family of kinases, causes diarrhea in a higher proportion of patients (76 to 84 percent) and is severe in approximately 9 percent [<a href="#rid222">222</a>]. (See  <a class="medical medical_review" href="/d/html/4515.html" rel="external">"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy", section on 'Bosutinib'</a>.)</p><p><a class="drug drug_general" data-topicid="87456" href="/d/drug information/87456.html" rel="external">Ponatinib</a> is a pan-BCR-ABL inhibitor; in contrast with other agents, diarrhea is uncommon with this drug [<a href="#rid223">223,224</a>].</p><p class="headingAnchor" id="H22"><span class="h3">Lapatinib, pertuzumab, neratinib, and tucatinib</span><span class="headingEndMark"> — </span>These are all drugs that target HER2 (EGFR2) and other EGFRs. The use of these agents to treat advanced HER2-positive breast cancer and metastatic HER2-positive colorectal cancer is discussed separately. (See  <a class="medical medical_review" href="/d/html/15749.html" rel="external">"Systemic treatment for HER2-positive metastatic breast cancer"</a> and  <a class="medical medical_review" href="/d/html/129349.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'RAS wild-type, HER2 overexpressors'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lapatinib</strong> – <a class="drug drug_general" data-topicid="10093" href="/d/drug information/10093.html" rel="external">Lapatinib</a>, an orally active TKI that affects both the HER2 (also called erbB-2) and EGFR (also called erbB-1), causes diarrhea in approximately 80 percent of patients; it is severe (grade 3 or 4) in 20 to 30 percent of patients [<a href="#rid225">225</a>]. Patients are typically managed with antidiarrheal agents such as <a class="drug drug_general" data-topicid="9571" href="/d/drug information/9571.html" rel="external">loperamide</a>. Severe diarrhea may require hydration, electrolyte repletion, and/or interruption of therapy (recommended for grade 3 toxicity)  (<a class="graphic graphic_table graphicRef65649" href="/d/graphic/65649.html" rel="external">table 1</a>), and grade 1 or 2 toxicity that is complicated by moderate to severe abdominal cramping, grade 2 or worse nausea or vomiting  (<a class="graphic graphic_table graphicRef69015" href="/d/graphic/69015.html" rel="external">table 9</a>), decreased performance status, sepsis, fever, neutropenia, bleeding, or dehydration). Treatment can be reintroduced at a lower dose when diarrhea resolves to grade 1 or less.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pertuzumab</strong> – <a class="drug drug_general" data-topicid="85639" href="/d/drug information/85639.html" rel="external">Pertuzumab</a> is a recombinant monoclonal antibody directed against HER2, but it does not require HER2 overexpression for activity. Treatment-related diarrhea is frequent, but not commonly severe [<a href="#rid226">226,227</a>]. In a study of pertuzumab monotherapy in patients with metastatic breast cancer, diarrhea of any grade developed in 48 percent, but it was severe (grade 3 or 4) in only 3 percent [<a href="#rid226">226</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neratinib</strong> – <a class="drug drug_general" data-topicid="114008" href="/d/drug information/114008.html" rel="external">Neratinib</a> is an orally active, irreversible TKI of HER1, HER2, and HER4, as well as EGFR; it is approved for extended adjuvant therapy in early stage HER2-positive breast cancer, and in combination with <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> for advanced HER2-positive breast cancer. (See  <a class="medical medical_review" href="/d/html/773.html" rel="external">"Adjuvant systemic therapy for HER2-positive breast cancer", section on 'Dual anti-HER2 therapy in high-risk disease'</a>.)</p><p></p><p class="bulletIndent1">With conventional dosing (240 mg daily starting immediately), treatment-related diarrhea occurs in almost all patients, and it is severe (grade 3 or 4) in approximately 40 percent in the absence of routine antidiarrheal prophylaxis [<a href="#rid228">228</a>]. The United States Prescribing information for <a class="drug drug_general" data-topicid="114008" href="/d/drug information/114008.html" rel="external">neratinib</a> recommends antidiarrheal prophylaxis with <a class="drug drug_general" data-topicid="9571" href="/d/drug information/9571.html" rel="external">loperamide</a> during the first two cycles (56 days) of treatment, initiated with the first dose, which improves tolerability [<a href="#rid229">229</a>]. Dose modifications for grade 2 to 4 diarrhea are also included in the prescribing information.</p><p></p><p class="bulletIndent1">Tolerability is improved with a gradually escalated initial dosing schedule (120 mg daily for one week, 160 mg daily for one week, followed by 240 mg daily thereafter, with only "as needed" <a class="drug drug_general" data-topicid="9571" href="/d/drug information/9571.html" rel="external">loperamide</a>), which was approved in 2021.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tucatinib</strong> – <a class="drug drug_general" data-topicid="127946" href="/d/drug information/127946.html" rel="external">Tucatinib</a> targets HER2 and HER3. Tucatinib can cause severe diarrhea with dehydration, hypotension, acute kidney injury, and death. The United States Prescribing Information for tucatinib does not recommend prophylactic antidiarrheal therapy, but has specific recommendations for dose interruption, reduction, and drug discontinuation for treatment-related diarrhea, depending on the severity [<a href="#rid230">230</a>].</p><p></p><p class="bulletIndent1">In the HER2Climb trial, over 80 percent of patients developed diarrhea during treatment with combined <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a>, <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>, and <a class="drug drug_general" data-topicid="127946" href="/d/drug information/127946.html" rel="external">tucatinib</a>, including 12 percent with grade 3 diarrhea and 0.5 percent with grade 4 diarrhea (both of whom died with diarrhea as a contributing cause) [<a href="#rid231">231</a>].</p><p></p><p class="headingAnchor" id="H112256291"><span class="h3">Cyclin-dependent kinase inhibitors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="99759" href="/d/drug information/99759.html" rel="external">Palbociclib</a>, <a class="drug drug_general" data-topicid="112288" href="/d/drug information/112288.html" rel="external">ribociclib</a>, and <a class="drug drug_general" data-topicid="115098" href="/d/drug information/115098.html" rel="external">abemaciclib</a> are oral inhibitors of cyclin-dependent kinases (CDK) 4 and 6; they are approved for treatment of hormone receptor-positive metastatic breast cancer. (See  <a class="medical medical_review" href="/d/html/778.html" rel="external">"Treatment for hormone receptor-positive, HER2-negative advanced breast cancer", section on 'AIs plus CDK 4/6 inhibitors'</a>.)</p><p>Diarrhea is a frequent adverse reaction with the CDK 4/6 inhibitors, especially with <a class="drug drug_general" data-topicid="115098" href="/d/drug information/115098.html" rel="external">abemaciclib</a>. Abemaciclib is more selective for CDK 4 compared with <a class="drug drug_general" data-topicid="99759" href="/d/drug information/99759.html" rel="external">palbociclib</a> and <a class="drug drug_general" data-topicid="112288" href="/d/drug information/112288.html" rel="external">ribociclib</a> and, as a result, causes more diarrhea and fatigue but fewer hematologic adverse events. Diarrhea occurs in 81 to 86 percent of treated patients, but it is typically low grade (severe in 10 to 13 percent) [<a href="#rid232">232,233</a>].</p><p><a class="drug drug_general" data-topicid="112288" href="/d/drug information/112288.html" rel="external">Ribociclib</a> has a much lower rate of diarrhea regardless of combination with <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>, an aromatase inhibitor, or with <a class="drug drug_general" data-topicid="8784" href="/d/drug information/8784.html" rel="external">fulvestrant</a>; approximately 33 percent of patients experience diarrhea of any grade and only 1 percent experience grade 3 or higher diarrhea [<a href="#rid234">234,235</a>]. <a class="drug drug_general" data-topicid="99759" href="/d/drug information/99759.html" rel="external">Palbociclib</a> may have the lowest rates of diarrhea with 26 percent of patients experiencing diarrhea of any grade and only 1.4 percent experiencing grade 3 diarrhea in the PALOMA-2 study of palbociclib combined with <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a> [<a href="#rid236">236</a>]. Diarrhea typically responds to antidiarrheal therapy, and treatment discontinuation is rarely needed.</p><p class="headingAnchor" id="H3295234606"><span class="h3">Trastuzumab antibody-drug conjugates</span><span class="headingEndMark"> — </span>Ado-trastuzumab-emtansine (T-DM1) is an antibody drug conjugate that consists of the HER2-targeting properties of <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> linked to the microtubule inhibitory agent DM1. As a treatment for advanced HER2-positive breast cancer, trastuzumab emtansine resulted in diarrhea in 23 percent of patients, but severe diarrhea occurred in fewer than 2 percent of patients [<a href="#rid237">237</a>]. (See  <a class="medical medical_review" href="/d/html/15749.html" rel="external">"Systemic treatment for HER2-positive metastatic breast cancer", section on 'Second-line treatment'</a>.)</p><p><a class="drug drug_general" data-topicid="126410" href="/d/drug information/126410.html" rel="external">Fam-trastuzumab deruxtecan</a> links the anti-HER2 antibody with a cytotoxic topoisomerase 1 inhibitor [<a href="#rid238">238</a>]. As a treatment for patients with advanced HER2-positive breast cancer previously treated with <a class="drug drug_general" data-topicid="88427" href="/d/drug information/88427.html" rel="external">ado-trastuzumab emtansine</a>, fam-trastuzumab deruxtecan was associated with diarrhea in 29 percent of patients and severe diarrhea in only 3 percent. (See  <a class="medical medical_review" href="/d/html/15749.html" rel="external">"Systemic treatment for HER2-positive metastatic breast cancer", section on 'Second-line treatment'</a> and  <a class="medical medical_review" href="/d/html/15749.html" rel="external">"Systemic treatment for HER2-positive metastatic breast cancer", section on 'Fam-trastuzumab deruxtecan'</a>.)</p><p class="headingAnchor" id="H3132729104"><span class="h3">Sacituzumab govitecan</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="127999" href="/d/drug information/127999.html" rel="external">Sacituzumab govitecan</a> is an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, a metabolite of <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>, which is conjugated to the antibody by a cleavable linker. It is approved for triple-negative breast cancer. (See  <a class="medical medical_review" href="/d/html/14227.html" rel="external">"ER/PR negative, HER2-negative (triple-negative) breast cancer", section on 'Sacituzumab govitecan'</a>.)</p><p>Severe diarrhea may occur with this agent, including cases of neutropenic colitis. In the IMMU-132-01 study, diarrhea occurred in 63 percent and was severe in 9 percent [<a href="#rid239">239</a>]. For patients who develop diarrhea, after infectious causes have been ruled out, <a class="drug drug_general" data-topicid="9571" href="/d/drug information/9571.html" rel="external">loperamide</a> should be initiated promptly, with additional supportive measures (fluids, electrolyte repletion) as clinically indicated. Grade 3 or 4 diarrhea that is not controlled with antidiarrheal agents should prompt dose reduction [<a href="#rid240">240</a>].</p><p>As with <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>, patients who inherit an <em>UGT1A1</em>*28 allele who receive <a class="drug drug_general" data-topicid="127999" href="/d/drug information/127999.html" rel="external">sacituzumab govitecan</a> are mainly at risk for excess neutropenia and not diarrhea. The United States Prescribing Information for sacituzumab govitecan does not provide any recommendation for lower initial doses of sacituzumab in patients known to be homozygous or heterozygous for the *28 allele [<a href="#rid120">120</a>]. (See <a class="local">'UGT1A1 polymorphisms'</a> above.)</p><p class="headingAnchor" id="H333420005"><span class="h3">Sotorasib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="131755" href="/d/drug information/131755.html" rel="external">Sotorasib</a> is an inhibitor of <em>RAS</em> GTPase family; it's approved for advanced non-small cell lung cancer with a <em>RAS</em> G12C mutation. (See  <a class="medical medical_review" href="/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer", section on 'Sotorasib'</a>.)</p><p>Diarrhea is reported in approximately 40 percent of treated patients, but it is severe in only 5 percent. The United States Prescribing Information provides guidance for dose management in patients with severe diarrhea despite appropriate supportive care (including antidiarrheal therapy) [<a href="#rid120">120</a>].</p><p class="headingAnchor" id="H23"><span class="h3">Temsirolimus and everolimus</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">Temsirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>, which are inhibitors of the mammalian target of rapamycin (mTOR), can cause diarrhea, but severe gastrointestinal toxicity is rare [<a href="#rid241">241,242</a>]. Diarrhea occurred in 27 percent of patients with renal cell carcinoma treated with temsirolimus but severe diarrhea occurred in only 1 percent [<a href="#rid242">242</a>]. In a placebo-controlled trial for treatment of advanced renal cell carcinoma, the incidence of diarrhea in the everolimus arm was 17 percent (1 percent grade 3) compared with 3 percent in the placebo arm (0 percent severe) [<a href="#rid241">241</a>]. In patients with advanced breast cancer, everolimus was associated with a 33 percent risk of diarrhea, but severe diarrhea was rare [<a href="#rid243">243</a>].</p><p class="headingAnchor" id="H1135608127"><span class="h3">ALK inhibitors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16810" href="/d/drug information/16810.html" rel="external">Crizotinib</a>, <a class="drug drug_general" data-topicid="95046" href="/d/drug information/95046.html" rel="external">ceritinib</a>, <a class="drug drug_general" data-topicid="105868" href="/d/drug information/105868.html" rel="external">alectinib</a>, and <a class="drug drug_general" data-topicid="112993" href="/d/drug information/112993.html" rel="external">brigatinib</a> are orally active inhibitors of the anaplastic lymphoma kinase (ALK); all are approved for treatment of advanced or metastatic NSCLC if the tumor contains a characteristic EML4-ALK fusion oncogene. (See  <a class="medical medical_review" href="/d/html/4621.html" rel="external">"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer", section on 'Ceritinib'</a> and  <a class="medical medical_review" href="/d/html/4621.html" rel="external">"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer", section on 'Crizotinib'</a>.)</p><p>Diarrhea is a common side effect, particularly with <a class="drug drug_general" data-topicid="95046" href="/d/drug information/95046.html" rel="external">ceritinib</a>, but rarely severe [<a href="#rid120">120</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a review of over 250 treated patients, the incidence of all-grade diarrhea with <a class="drug drug_general" data-topicid="95046" href="/d/drug information/95046.html" rel="external">ceritinib</a> was 86 percent; it was severe (≥grade 3) in 6 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a review of 397 patients treated with <a class="drug drug_general" data-topicid="16810" href="/d/drug information/16810.html" rel="external">crizotinib</a>, 49 percent developed diarrhea of any grade, and it was severe in &lt;1 percent.</p><p></p><p>Diarrhea seems to be significantly less frequent with <a class="drug drug_general" data-topicid="105868" href="/d/drug information/105868.html" rel="external">alectinib</a>, a newer agent with more potent ALK inhibitory activity and better central nervous system penetration. In the randomized phase III ALEX study comparing alectinib with <a class="drug drug_general" data-topicid="16810" href="/d/drug information/16810.html" rel="external">crizotinib</a>, diarrhea was significantly less common with alectinib (12 versus 45 percent), and there were no patients with grade 3 or higher diarrhea [<a href="#rid244">244</a>].</p><p class="headingAnchor" id="H12219659"><span class="h3">MEK inhibitors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="105354" href="/d/drug information/105354.html" rel="external">Cobimetinib</a>, <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a>, and <a class="drug drug_general" data-topicid="118324" href="/d/drug information/118324.html" rel="external">binimetinib</a> are orally active inhibitors of the mitogen-activated protein kinase enzymes MEK1/MEK2; they are approved for treatment of metastatic melanoma with the <em>BRAF</em><em><sup> </sup></em>V600 mutation in combination with their respective BRAF inhibitor partners, <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a>, <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a>, and <a class="drug drug_general" data-topicid="118325" href="/d/drug information/118325.html" rel="external">encorafenib</a>. The combination of dabrafenib and trametinib is FDA approved for treatment of metastatic NSCLC with a <em>BRAF</em><em><sup> </sup></em>V600 mutation. Encorafenib is FDA approved in combination with the EGFR inhibitor <a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a> for treatment of metastatic colon cancer with the <em>BRAF</em><em><sup> </sup></em>V600E mutation. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Toxicities of BRAF and MEK inhibitors'</a>.)</p><p>Diarrhea is a frequent complication of these drugs. In clinical trials, approximately one-half of patients develop diarrhea, but it is severe (grade 3 or worse) in fewer than 5 percent of cases [<a href="#rid245">245-247</a>]. The United States Prescribing Information for these drugs recommends withholding the drug for grade 2 or worse adverse reactions, including diarrhea  (<a class="graphic graphic_table graphicRef65649" href="/d/graphic/65649.html" rel="external">table 1</a>), and permanent discontinuation if toxicity does not improve to grade 0-1 within three or four weeks or for any recurrent grade 4 toxicity.</p><p class="headingAnchor" id="H10876800"><span class="h3">BTK inhibitors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">Ibrutinib</a>, <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a>, and <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> are orally active inhibitors of Bruton’s tyrosine kinase (BTK), a nonreceptor kinase that is critical for proliferation and survival of the malignant cells in many B-cell malignancies. (See  <a class="medical medical_review" href="/d/html/4520.html" rel="external">"Treatment of relapsed or refractory chronic lymphocytic leukemia", section on 'Ibrutinib'</a> and  <a class="medical medical_review" href="/d/html/4735.html" rel="external">"Treatment of relapsed or refractory mantle cell lymphoma", section on 'Bruton tyrosine kinase inhibitors'</a>.)</p><p>In a phase III trial, the incidence of treatment-related diarrhea with <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> was 42 percent; only 4 percent of patients had severe (grade 3 or 4) diarrhea  (<a class="graphic graphic_table graphicRef65649" href="/d/graphic/65649.html" rel="external">table 1</a>) [<a href="#rid248">248</a>]. The United States Prescribing Information provides specific guidelines for dose reduction in response to adverse events, including diarrhea [<a href="#rid120">120</a>].</p><p>The risk of diarrhea was slightly less (all-grade 34.1 percent, 0.6 percent grade 3 or worse) in the monotherapy arm of the phase III ELEVATE TN trial of <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> [<a href="#rid249">249,250</a>]. The United States Prescribing Information provides specific guidelines for dose reduction in the setting of grade 3 or higher nonhematologic toxicity [<a href="#rid120">120</a>].</p><p class="headingAnchor" id="H2270801934"><span class="h3">FGFR inhibitors</span><span class="headingEndMark"> — </span>Three oral tyrosine kinase inhibitors of the fibroblast growth factor receptor (FGFR) are approved for cancer treatment: <a class="drug drug_general" data-topicid="121054" href="/d/drug information/121054.html" rel="external">erdafitinib</a>, <a class="drug drug_general" data-topicid="131754" href="/d/drug information/131754.html" rel="external">infigratinib</a>, and <a class="drug drug_general" data-topicid="127947" href="/d/drug information/127947.html" rel="external">pemigatinib</a>. All three drugs have been associated with diarrhea in approximately one-half of treated patients that is severe in less than 5 percent.</p><p class="headingAnchor" id="H4073526834"><span class="h3">PARP inhibitors</span><span class="headingEndMark"> — </span>The poly(ADP-ribose) polymerase (PARP) inhibitors, which include <a class="drug drug_general" data-topicid="98761" href="/d/drug information/98761.html" rel="external">olaparib</a>, <a class="drug drug_general" data-topicid="111396" href="/d/drug information/111396.html" rel="external">rucaparib</a>, and <a class="drug drug_general" data-topicid="112483" href="/d/drug information/112483.html" rel="external">niraparib</a>, are a novel class of drugs targeting DNA repair mechanisms that are best studied in ovarian cancer, but olaparib also has approvals in breast, pancreatic, and prostate cancer. Both diarrhea and constipation are frequently reported in trials of these drugs, but they were also common in the placebo arms of these studies. This is likely because bowel dysfunction is common in ovarian cancer due to high rates of peritoneal involvement.</p><p>For <a class="drug drug_general" data-topicid="98761" href="/d/drug information/98761.html" rel="external">olaparib</a> and <a class="drug drug_general" data-topicid="111396" href="/d/drug information/111396.html" rel="external">rucaparib</a>, both constipation and diarrhea are reported in approximately 30 percent of patients [<a href="#rid251">251-253</a>]. <a class="drug drug_general" data-topicid="112483" href="/d/drug information/112483.html" rel="external">Niraparib</a> on the other hand is more frequently associated with constipation (40 percent of patients) but causes diarrhea less often (19 percent) [<a href="#rid254">254</a>].</p><p class="headingAnchor" id="H3603048751"><span class="h3">Rituximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a>, an anti-CD20 monoclonal antibody used to treat B-cell lymphoma, can cause new-onset ulcerative colitis or exacerbation of preexisting colitis [<a href="#rid255">255</a>].</p><p class="headingAnchor" id="H3124101798"><span class="h2">Risk with immune checkpoint inhibitors</span><span class="headingEndMark"> — </span>A wide range of immune-mediated adverse events have been observed in patients treated with immune checkpoint inhibitors, including enterocolitis, which can be serious or life-threatening. It is critical to recognize that treatment of diarrhea caused by immune checkpoint inhibitors may require systemic glucocorticoids. The manifestations and management of checkpoint inhibitor immunotherapy-induced enterocolitis are discussed separately. (See  <a class="medical medical_review" href="/d/html/138429.html" rel="external">"Immune checkpoint inhibitor colitis"</a>.)</p><p class="headingAnchor" id="H4253980216"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Management of acute chemotherapy-related diarrhea is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/98342.html" rel="external">"Management of acute chemotherapy-related diarrhea"</a>.)</p><p class="headingAnchor" id="H36"><span class="h1">CONSTIPATION</span><span class="headingEndMark"> — </span>Constipation can be defined as a decreased frequency of defecation (usually less than three bowel movements per week) accompanied by discomfort or difficulty with evacuating the bowels. It is a common problem in patients with cancer, with a reported prevalence of 40 to 90 percent in patients with advanced cancer [<a href="#rid256">256</a>]. Constipation in patients with cancer is usually due to a combination of poor oral intake and drugs, such as opioid analgesics or antiemetic agents that slow intestinal transit time. As an example, 5HT3 receptors are present on enteric neurons, and <a class="drug drug_general" data-topicid="9719" href="/d/drug information/9719.html" rel="external">ondansetron</a> was shown to slow colonic transit time in healthy subjects [<a href="#rid257">257</a>]. (See  <a class="medical medical_review" href="/d/html/2800.html" rel="external">"Prevention and management of side effects in patients receiving opioids for chronic pain", section on 'Opioid bowel dysfunction'</a>.)</p><p>Constipation can have a significant detrimental impact on quality of life and can lead to nausea, vomiting, hemorrhoids, anal fissures, bowel obstruction, and urinary retention [<a href="#rid256">256</a>]. Overflow diarrhea can occur from fecal leakage around impacted stool [<a href="#rid258">258</a>].</p><p class="headingAnchor" id="H1089123858"><span class="h2">Specific cancer drugs associated with constipation</span></p><p class="headingAnchor" id="H37"><span class="h3">Vinca alkaloids</span><span class="headingEndMark"> — </span>Constipation is rarely a dose-limiting toxicity for chemotherapeutic agents, except for the vinca alkaloids (eg, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, and <a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">vinorelbine</a>), especially vincristine. (See  <a class="medical medical_review" href="/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Vincristine'</a>.)</p><p>These drugs have pronounced neuropathic effects and increase gastrointestinal (GI) transit time [<a href="#rid259">259</a>]. The constipating effect of vinca alkaloid therapy is usually apparent after the first dose and is typically not cumulative. It is most prominent 3 to 10 days after chemotherapy and then resolves, in most cases, after a few days [<a href="#rid260">260</a>].</p><p>Constipation occurs in one-quarter to one-third of patients treated with <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a> [<a href="#rid261">261,262</a>] and is severe  (<a class="graphic graphic_table graphicRef117320" href="/d/graphic/117320.html" rel="external">table 10</a>) in 2 to 3 percent [<a href="#rid261">261,263</a>]. In one series of 392 patients, 2.8 percent required hospitalization for adynamic ileus [<a href="#rid261">261</a>].</p><p>Vincristine-induced constipation is more severe at higher doses (above 2 mg). This was illustrated in a report of 104 patients with Hodgkin or non-Hodgkin lymphoma [<a href="#rid264">264</a>]. <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">Vincristine</a> was given in a non-capped dose of 1.4 mg/m<sup>2</sup>, and 90 percent of patients received more than 2 mg in the first dose. Severe constipation occurred in 10 percent. Rapid improvement usually occurred within a few weeks after the cessation of therapy.</p><p class="headingAnchor" id="H38"><span class="h3">Immunomodulatory imide (IMiD) drugs</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">Thalidomide</a> and its analogs <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> and <a class="drug drug_general" data-topicid="88099" href="/d/drug information/88099.html" rel="external">pomalidomide</a> are immunomodulatory imide drugs (IMiDs) that are approved for the treatment of multiple myeloma. Lenalidomide is also approved for treatment of certain types of lymphoma and myelodysplastic syndrome. Thalidomide is also approved for treatment of erythema nodosum leprosum. (See  <a class="medical medical_review" href="/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies", section on 'Immunomodulatory drugs'</a>.)</p><p>The most common toxicity with <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a>, besides sedation, is constipation. In a major myeloma trial, constipation developed in 35 percent of patients at 200 mg/day and in 59 percent at 800 mg/day [<a href="#rid265">265</a>]. These rates seem higher than those observed in a phase II trial of thalidomide (starting dose 800 mg daily) in patients with recurrent high-grade glioma, in which constipation was the most common toxicity but only occurred in 19 percent of patients; no severe episodes were noted [<a href="#rid266">266</a>].</p><p>Thalidomide-induced constipation is dose dependent, appears early after the initiation of therapy (within two to four days) in most patients, and is more severe in older adults and in those receiving opioid analgesics [<a href="#rid267">267</a>]. The mechanism might be neuromuscular inertia with resultant hypotonia. Thalidomide-induced hypothyroidism should be considered in patients with persistent constipation or if it appears late in the disease course.</p><p><a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">Lenalidomide</a>, an immunomodulatory agent derived from <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a>, is used more frequently than thalidomide for treatment of multiple myeloma due to its efficacy and reduced toxicity, including constipation. When added to <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, the incidence of constipation was 30 percent, but severe constipation occurred in less than 3 percent of patients [<a href="#rid268">268,269</a>]. Lenalidomide maintenance therapy after autologous stem cell transplantation has not been associated with frequent constipation [<a href="#rid270">270</a>].</p><p>In clinical trials, <a class="drug drug_general" data-topicid="88099" href="/d/drug information/88099.html" rel="external">pomalidomide</a> has been associated with diarrhea or constipation in approximately one-third of treated patients, none of which were severe [<a href="#rid271">271</a>].</p><p class="headingAnchor" id="H19930479"><span class="h3">Vandetanib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16484" href="/d/drug information/16484.html" rel="external">Vandetanib</a> is a multitargeted inhibitor of several tyrosine kinases. In clinical trials involving patients with medullary thyroid cancer and lung cancer, vandetanib was associated with constipation in 9 to 37 percent of patients, with 0 to 3 percent severe [<a href="#rid272">272-274</a>]. Vandetanib is more often associated with diarrhea. (See <a class="local">'Small molecule inhibitors of VEGFR'</a> above.)</p><p class="headingAnchor" id="H91239438"><span class="h3">Belinostat</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="96188" href="/d/drug information/96188.html" rel="external">Belinostat</a> is a histone deacetylase inhibitor that is approved for treatment of peripheral T-cell lymphoma. In an initial clinical trial involving 129 patients, belinostat was associated with constipation in 23 percent of patients, with 2 percent severe [<a href="#rid185">185</a>]. Diarrhea was equally common. (See <a class="local">'Vorinostat and belinostat'</a> above.)</p><p class="headingAnchor" id="H39"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>The treatment of chemotherapy-induced constipation begins with anticipation and prevention:</p><p class="bulletIndent1"><span class="glyph">●</span>We encourage increased fluid intake.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laxatives should be started at the first sign of constipation or, for patients treated with agents that are known to be associated with constipation (eg, vinca alkaloids), given routinely to prevent constipation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The most frequently used laxatives in patients with advanced cancer are osmotic agents (such as polyethylene glycol and <a class="drug drug_general" data-topicid="9543" href="/d/drug information/9543.html" rel="external">lactulose</a>) and stimulant laxatives (eg, <a class="drug drug_general" data-topicid="10260" href="/d/drug information/10260.html" rel="external">senna</a> and <a class="drug drug_general" data-topicid="8815" href="/d/drug information/8815.html" rel="external">bisacodyl</a>) [<a href="#rid256">256</a>]. The Multinational Association for Supportive Care in Cancer (MASCC) recommended polyethylene glycol as the initial laxative of choice for patients with advanced cancer based on evidence in the general population, expert opinion, and clinical experience [<a href="#rid258">258</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients should be frequently reassessed for response to treatment with changes or additions made to the treatment regimen [<a href="#rid258">258</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonabsorbable soluble dietary fiber or bulk agents should be avoided in patients with low fluid intake due to increased risk of mechanical bowel obstruction [<a href="#rid256">256</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We do not routinely prescribe <a class="drug drug_general" data-topicid="9382" href="/d/drug information/9382.html" rel="external">docusate</a> sodium for constipation. A randomized trial of sennosides with docusate sodium or placebo found no improvement in constipation in hospice patients [<a href="#rid275">275</a>].</p><p></p><p>A summary of dose, onset of action, and side effects for a variety of agents for chronic constipation is provided in the table  (<a class="graphic graphic_table graphicRef59746" href="/d/graphic/59746.html" rel="external">table 11</a>). (See  <a class="medical medical_review" href="/d/html/2636.html" rel="external">"Management of chronic constipation in adults"</a>.)</p><p>Management of opioid-induced constipation is addressed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2800.html" rel="external">"Prevention and management of side effects in patients receiving opioids for chronic pain", section on 'Opioid bowel dysfunction'</a>.)</p><p class="headingAnchor" id="H45"><span class="h1">INTESTINAL PERFORATION</span><span class="headingEndMark"> — </span>Bowel perforation is an uncommonly encountered complication that seems to be associated with antiangiogenic agents, particularly <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>, a monoclonal antibody targeting the vascular endothelial growth factor (VEGF).</p><p>This complication is not unique to agents that target angiogenesis. Bowel perforation has also been seen (albeit rarely) with other tumors involving the gastrointestinal (GI) tract that respond rapidly to conventional cytotoxic chemotherapy (eg, GI tract lymphomas). (See  <a class="medical medical_review" href="/d/html/4710.html" rel="external">"Treatment of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT lymphoma)"</a>.)</p><p class="headingAnchor" id="H46"><span class="h2">Angiogenesis inhibitors</span><span class="headingEndMark"> — </span>All VEGF-targeted therapies, including <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="94963" href="/d/drug information/94963.html" rel="external">ramucirumab</a>, <a class="drug drug_general" data-topicid="17100" href="/d/drug information/17100.html" rel="external">aflibercept</a>, and the orally active antiangiogenic tyrosine kinase inhibitors (TKIs), can cause GI perforation (GIP), although this complication is best described in patients receiving bevacizumab [<a href="#rid18">18,276-278</a>]. GIP has been reported in patients treated with bevacizumab for a variety of malignancies but is most often described in the setting of metastatic colorectal cancer and epithelial ovarian cancer. GIP can occur anywhere along the GI tract, often away from tumor sites or prior surgical anastomoses. (See  <a class="medical medical_review" href="/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Intestinal perforation/fistula formation'</a>.)</p><p>Although several risk factors have been described for GIP during <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> treatment, bowel perforation may occur even in the absence of predisposing risk factors, and it remains difficult to predict which patients will develop this complication. Many cases involve perforation of an in situ bowel primary. However, GIP can also occur at previously resected primary sites, often in the setting of previous irradiation or a prior anastomotic leak. GIP can also occur during bevacizumab treatment of malignancies that lack disease within the peritoneal cavity (eg, primary malignant brain tumors) [<a href="#rid279">279</a>]. In a community-based observational study of patients with metastatic colorectal cancer treated with bevacizumab, 1.9 percent experienced GIP [<a href="#rid280">280</a>]. Most GIP occurred ≤6 months after starting bevacizumab (median, 3.35 months). There was no cumulative risk of GIP with bevacizumab exposure. The US Food and Drug Administration (FDA) label for bevacizumab states that the majority of cases occurred within the first 50 days of initiation of bevacizumab.</p><p>In order to minimize the risk of GIP and fistula formation, at least 28 days (preferably six to eight weeks) should elapse between surgery and the last dose of <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>, except in emergency situations. Clinicians should maintain a high index of suspicion for GIP in patients who develop acute abdominal pain while receiving bevacizumab, even if they have no apparent risk factors.</p><p>Perforation may be asymptomatic, or it can present with abdominal pain from peritoneal contamination, free air, hemoperitoneum, or an intra-abdominal abscess. Patients with confirmed or highly suspected GIP whose overall condition is unstable secondary to the GIP should be considered for immediate surgical repair or diversion. Those who are more stable can be considered for less invasive management strategies such as bowel rest and broad-spectrum antibiotics with or without percutaneous drainage of concurrent abscesses. The timing of the presentation, the patient's overall condition, their goals and wishes, and overall prognosis are important factors in the decision to explore these patients surgically. This subject is addressed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Intestinal perforation/fistula formation'</a>.)</p><p class="headingAnchor" id="H48"><span class="h2">Thalidomide in multiple myeloma</span><span class="headingEndMark"> — </span>At least one case report describes four cases of bowel perforation in patients receiving <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a> for multiple myeloma [<a href="#rid281">281</a>]. The true incidence is unknown.</p><p class="headingAnchor" id="H49"><span class="h2">EGFR inhibitors</span><span class="headingEndMark"> — </span>Cases of GIP (some fatal) have also been reported in patients receiving the small-molecule epidermal growth factor receptor (EGFR) inhibitor <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a> and <a class="drug drug_general" data-topicid="8712" href="/d/drug information/8712.html" rel="external">gefitinib</a> [<a href="#rid282">282</a>]. (See  <a class="medical medical_review" href="/d/html/4630.html" rel="external">"Systemic therapy for advanced non-small cell lung cancer with an activating mutation in the epidermal growth factor receptor", section on 'EGFR TKI toxicity'</a>.)</p><p class="headingAnchor" id="H1736673912"><span class="h2">Idelalisib</span><span class="headingEndMark"> — </span>Fatal and serious intestinal perforation has occurred in patients treated with <a class="drug drug_general" data-topicid="96416" href="/d/drug information/96416.html" rel="external">idelalisib</a>, an oral inhibitor of phosphoinositide 3-kinase (PI3K) delta that is approved for treatment of relapsed chronic lymphocytic leukemia, follicular lymphoma, and small lymphocytic lymphoma. At the time of perforation, some patients have had moderate to severe diarrhea. Idelalisib should be discontinued permanently in patients who experience intestinal perforation. (See <a class="local">'PI3K inhibitors'</a> above.)</p><p class="headingAnchor" id="H2394382662"><span class="h2">Trametinib</span><span class="headingEndMark"> — </span>The MEK inhibitor <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a> has been associated with GIP. Across clinical trials of trametinib administered as a single agent or in combination with <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a>, the risk of GIP was less than 1 percent [<a href="#rid283">283</a>].</p><p class="headingAnchor" id="H204887526"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chemotherapy-related diarrhea</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute chemotherapy-related diarrhea (CRD) is most commonly described with fluoropyrimidines (particularly <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> [FU] and <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>), <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>, <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a>, and <a class="drug drug_general" data-topicid="15577" href="/d/drug information/15577.html" rel="external">cabazitaxel</a>. (See <a class="local">'Risk with conventional cytotoxic agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme in fluoropyrimidine catabolism, and enzyme activity varies widely mostly due to genetic polymorphisms in the DPD gene (<em>DPYD)</em>. (See <a class="local">'Fluorouracil'</a> above and <a class="local">'Capecitabine'</a> above.)</p><p></p><p class="bulletIndent2">Testing is commercially available that might identify patients who are at risk for severe toxicity from fluoropyrimidines based upon <em>DPYD</em> and <em>TYMS</em> genotype. However, we do not routinely test <em>DPYD</em> and/or <em>TYMS</em> genotype for all patients initiating fluoropyrimidine therapy. We advocate testing for a panel of relevant DPD alleles (rather than just <em>DPYD</em>*2A) plus <em>TYMS</em> genotyping in patients who have had severe and unexpected toxicity from fluoropyrimidines (<a class="graphic graphic_table graphicRef109665" href="/d/graphic/109665.html" rel="external">table 2</a>). (See <a class="local">'Testing for DPYD and TYMS variants'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Late diarrhea from <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> is unpredictable, noncumulative, and not dose-dependent. Strict adherence to management guidelines (including early institution of high-dose <a class="drug drug_general" data-topicid="9571" href="/d/drug information/9571.html" rel="external">loperamide</a>) and the use of infusional rather than bolus FU in combination with irinotecan has reduced the incidence. Preemptive testing for <em>UGT1A1</em> genotypes that are associated with a poor metabolizer phenotype prior to initiating irinotecan is a controversial and evolving area, and experts differ. At our institution preemptive testing is recommended for all such individuals, and we reduce initial starting doses by approximately 30 percent if a high-risk genotype is identified. (See <a class="local">'Irinotecan'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute chemotherapy-related diarrhea is also common with <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a> and <a class="drug drug_general" data-topicid="9491" href="/d/drug information/9491.html" rel="external">vorinostat</a>. (See <a class="local">'Bortezomib and other proteasome inhibitors'</a> above and <a class="local">'Vorinostat and belinostat'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The most common molecularly targeted agents associated with CRD are small-molecule tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), especially <a class="drug drug_general" data-topicid="90144" href="/d/drug information/90144.html" rel="external">afatinib</a> and <a class="drug drug_general" data-topicid="114008" href="/d/drug information/114008.html" rel="external">neratinib</a>; anaplastic lymphoma kinase (ALK) inhibitors such as <a class="drug drug_general" data-topicid="95046" href="/d/drug information/95046.html" rel="external">ceritinib</a>; the CDK4/6 inhibitor <a class="drug drug_general" data-topicid="115098" href="/d/drug information/115098.html" rel="external">abemaciclib</a>; combinations of MEK and BRAF inhibitors such as <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a>/<a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> and <a class="drug drug_general" data-topicid="118324" href="/d/drug information/118324.html" rel="external">binimetinib</a>/<a class="drug drug_general" data-topicid="118325" href="/d/drug information/118325.html" rel="external">encorafenib</a>; the Bruton tyrosine kinase (BTK) inhibitor <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a>; and the phosphoinositide 3-kinase (PI3K) inhibitors <a class="drug drug_general" data-topicid="96416" href="/d/drug information/96416.html" rel="external">idelalisib</a>, <a class="drug drug_general" data-topicid="119167" href="/d/drug information/119167.html" rel="external">duvelisib</a>, and <a class="drug drug_general" data-topicid="121400" href="/d/drug information/121400.html" rel="external">alpelisib</a>. (See <a class="local">'Risk with molecularly targeted agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Constipation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Constipation is rarely dose-limiting for chemotherapeutic agents, except for <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>, <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a>, and <a class="drug drug_general" data-topicid="88099" href="/d/drug information/88099.html" rel="external">pomalidomide</a>. (See <a class="local">'Vinca alkaloids'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment should focus on anticipation and prevention. Laxatives should be started at the first sign of constipation or should be given routinely to prevent constipation. (See <a class="local">'Constipation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bowel perforation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bowel perforation is an uncommonly encountered complication that seems to be associated with antiangiogenic agents, particularly <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>, a monoclonal antibody targeting vascular endothelial growth factor (VEGF). (See <a class="local">'Intestinal perforation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bowel perforation is rarely reported with EGFR inhibitors, MEK inhibitors, PI3K delta inhibitors, <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a>, and immunotherapy.</p><p></p><p class="headingAnchor" id="H2861001218"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Smitha S Krishnamurthi, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Di Fiore F, Van Cutsem E. Acute and long-term gastrointestinal consequences of chemotherapy. Best Pract Res Clin Gastroenterol 2009; 23:113.</a></li><li><a class="nounderline abstract_t">Milles SS, Muggia AL, Spiro HM. Colonic histological changes induced by 5-fluorouracil. Gastroenterology 1962; 43:391.</a></li><li><a class="nounderline abstract_t">Ikuno N, Soda H, Watanabe M, Oka M. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst 1995; 87:1876.</a></li><li><a class="nounderline abstract_t">Gibson RJ, Bowen JM, Inglis MR, et al. Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol 2003; 18:1095.</a></li><li><a class="nounderline abstract_t">Stringer AM, Gibson RJ, Logan RM, et al. Irinotecan-induced mucositis is associated with changes in intestinal mucins. Cancer Chemother Pharmacol 2009; 64:123.</a></li><li><a class="nounderline abstract_t">Kawato Y, Aonuma M, Hirota Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991; 51:4187.</a></li><li><a class="nounderline abstract_t">Keefe D, Anthony L. Tyrosine kinase inhibitors and gut toxicity: a new era in supportive care. Curr Opin Support Palliat Care 2008; 2:19.</a></li><li><a class="nounderline abstract_t">Loriot Y, Perlemuter G, Malka D, et al. Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol 2008; 5:268.</a></li><li><a class="nounderline abstract_t">Uribe JM, Gelbmann CM, Traynor-Kaplan AE, Barrett KE. Epidermal growth factor inhibits Ca(2+)-dependent Cl- transport in T84 human colonic epithelial cells. Am J Physiol 1996; 271:C914.</a></li><li><a class="nounderline abstract_t">Parnes HL, Fung E, Schiffer CA. Chemotherapy-induced lactose intolerance in adults. Cancer 1994; 74:1629.</a></li><li><a class="nounderline abstract_t">Osterlund P, Ruotsalainen T, Peuhkuri K, et al. Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer. Clin Gastroenterol Hepatol 2004; 2:696.</a></li><li><a class="nounderline abstract_t">Pearson AD, Craft AW, Pledger JV, et al. Small bowel function in acute lymphoblastic leukaemia. Arch Dis Child 1984; 59:460.</a></li><li><a class="nounderline abstract_t">Pettoello-Mantovani M, Guandalini S, diMartino L, et al. Prospective study of lactose absorption during cancer chemotherapy: feasibility of a yogurt-supplemented diet in lactose malabsorbers. J Pediatr Gastroenterol Nutr 1995; 20:189.</a></li><li><a class="nounderline abstract_t">Holma R, Laatikainen R, Orell H, et al. Consumption of Lactose, Other FODMAPs and Diarrhoea during Adjuvant 5-Fluorouracil Chemotherapy for Colorectal Cancer. Nutrients 2020; 12.</a></li><li><a class="nounderline abstract_t">Abigerges D, Chabot GG, Armand JP, et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995; 13:210.</a></li><li><a class="nounderline abstract_t">Ropert S, Vignaux O, Mir O, Goldwasser F. VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption. Invest New Drugs 2011; 29:1497.</a></li><li><a class="nounderline abstract_t">Lazarescu RE, Bohm K. An unusual case of bowel perforation. BMJ Case Rep 2014; 2014.</a></li><li><a class="nounderline abstract_t">Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335.</a></li><li><a class="nounderline abstract_t">Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26:2013.</a></li><li><a class="nounderline abstract_t">Tang T, Abu-Sbeih H, Ma W, et al. Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy. Clin Colorectal Cancer 2020; 19:e117.</a></li><li><a class="nounderline abstract_t">Arbuckle RB, Huber SL, Zacker C. The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study. Oncologist 2000; 5:250.</a></li><li><a class="nounderline abstract_t">Aksoy DY, Tanriover MD, Uzun O, et al. Diarrhea in neutropenic patients: a prospective cohort study with emphasis on neutropenic enterocolitis. Ann Oncol 2007; 18:183.</a></li><li><a class="nounderline abstract_t">Krishna SG, Zhao W, Grazziutti ML, et al. Incidence and risk factors for lower alimentary tract mucositis after 1529 courses of chemotherapy in a homogenous population of oncology patients: clinical and research implications. Cancer 2011; 117:648.</a></li><li><a class="nounderline abstract_t">Ibrahim NK, Sahin AA, Dubrow RA, et al. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet 2000; 355:281.</a></li><li><a class="nounderline abstract_t">Kreis W, Petrylak D, Savarese D, Budman D. Colitis and docetaxel-based chemotherapy. Lancet 2000; 355:2164.</a></li><li><a class="nounderline abstract_t">Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993; 17:109.</a></li><li><a class="nounderline abstract_t">Emoto M, Kawarabayashi T, Hachisuga MD, et al. Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients. Gynecol Oncol 1996; 61:369.</a></li><li><a class="nounderline abstract_t">Kamthan AG, Bruckner HW, Hirschman SZ, Agus SG. Clostridium difficile diarrhea induced by cancer chemotherapy. Arch Intern Med 1992; 152:1715.</a></li><li><a class="nounderline abstract_t">Husain A, Aptaker L, Spriggs DR, Barakat RR. Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens. Gynecol Oncol 1998; 71:104.</a></li><li><a class="nounderline abstract_t">Ghiringhelli F, Vincent J, Beltjens F, et al. Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients. Invest New Drugs 2015; 33:1263.</a></li><li><a class="nounderline abstract_t">Grem JL, Shoemaker DD, Petrelli NJ, Douglass HO Jr. Severe life-threatening toxicities observed in study using leucovorin with 5-fluorouracil. J Clin Oncol 1987; 5:1704.</a></li><li><a class="nounderline abstract_t">Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987; 5:1559.</a></li><li><a class="nounderline abstract_t">Leichman CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995; 13:1303.</a></li><li><a class="nounderline abstract_t">Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7:1407.</a></li><li><a class="nounderline abstract_t">Petrelli N, Douglass HO Jr, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989; 7:1419.</a></li><li><a class="nounderline abstract_t">Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352:476.</a></li><li><a class="nounderline abstract_t">Cascinu S, Barni S, Labianca R, et al. Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) study. Support Care Cancer 1997; 5:314.</a></li><li><a class="nounderline abstract_t">Dranitsaris G, Shah A, Spirovski B, Vincent M. Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool. Clin Colorectal Cancer 2007; 6:367.</a></li><li><a class="nounderline abstract_t">Kuebler JP, Colangelo L, O'Connell MJ, et al. Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis. Cancer 2007; 110:1945.</a></li><li><a class="nounderline abstract_t">Sloan JA, Goldberg RM, Sargent DJ, et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 2002; 20:1491.</a></li><li><a class="nounderline abstract_t">Chansky K, Benedetti J, Macdonald JS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer 2005; 103:1165.</a></li><li><a class="nounderline abstract_t">Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988; 81:47.</a></li><li><a class="nounderline abstract_t">Maring JG, van Kuilenburg AB, Haasjes J, et al. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br J Cancer 2002; 86:1028.</a></li><li><a class="nounderline abstract_t">Ezzeldin H, Johnson MR, Okamoto Y, Diasio R. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clin Cancer Res 2003; 9:3021.</a></li><li><a class="nounderline abstract_t">Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer 1991; 68:499.</a></li><li><a class="nounderline abstract_t">Takimoto CH, Lu ZH, Zhang R, et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 1996; 2:477.</a></li><li><a class="nounderline abstract_t">Ezzeldin H, Diasio R. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer 2004; 4:181.</a></li><li><a class="nounderline abstract_t">Diasio RB, Johnson MR. Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res 1999; 5:2672.</a></li><li><a class="nounderline abstract_t">van Kuilenburg AB, Meinsma R, Zonnenberg BA, et al. Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin Cancer Res 2003; 9:4363.</a></li><li><a class="nounderline abstract_t">Yang CG, Ciccolini J, Blesius A, et al. DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. Cancer Chemother Pharmacol 2011; 67:49.</a></li><li><a class="nounderline abstract_t">Morel A, Boisdron-Celle M, Fey L, et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 2006; 5:2895.</a></li><li><a class="nounderline abstract_t">van Kuilenburg AB, De Abreu RA, van Gennip AH. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann Clin Biochem 2003; 40:41.</a></li><li><a class="nounderline abstract_t">Offer SM, Fossum CC, Wegner NJ, et al. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res 2014; 74:2545.</a></li><li><a class="nounderline abstract_t">Johnson MR, Diasio RB. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul 2001; 41:151.</a></li><li><a class="nounderline abstract_t">Johnson MR, Wang K, Diasio RB. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res 2002; 8:768.</a></li><li><a class="nounderline abstract_t">Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008; 26:2131.</a></li><li><a class="nounderline abstract_t">Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g&gt;a mutation. Int J Cancer 2002; 101:253.</a></li><li><a class="nounderline abstract_t">Raida M, Schwabe W, Häusler P, et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin Cancer Res 2001; 7:2832.</a></li><li><a class="nounderline abstract_t">Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH. High prevalence of the IVS14 + 1G&gt;A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002; 12:555.</a></li><li><a class="nounderline abstract_t">Deenen MJ, Tol J, Burylo AM, et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res 2011; 17:3455.</a></li><li><a class="nounderline abstract_t">Loganayagam A, Arenas Hernandez M, Corrigan A, et al. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer 2013; 108:2505.</a></li><li><a class="nounderline abstract_t">Deenen MJ, Meulendijks D, Cats A, et al. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. J Clin Oncol 2016; 34:227.</a></li><li><a class="nounderline abstract_t">Terrazzino S, Cargnin S, Del Re M, et al. DPYD IVS14+1G&gt;A and 2846A&gt;T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics 2013; 14:1255.</a></li><li><a class="nounderline abstract_t">Meulendijks D, Henricks LM, Sonke GS, et al. Clinical relevance of DPYD variants c.1679T&gt;G, c.1236G&gt;A/HapB3, and c.1601G&gt;A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 2015; 16:1639.</a></li><li><a class="nounderline abstract_t">Amstutz U, Farese S, Aebi S, Largiadèr CR. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics 2009; 10:931.</a></li><li><a class="nounderline abstract_t">Meulendijks D, Henricks LM, van Kuilenburg AB, et al. Patients homozygous for DPYD c.1129-5923C&gt;G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines. Cancer Chemother Pharmacol 2016; 78:875.</a></li><li><a class="nounderline abstract_t">van Kuilenburg AB, Meijer J, Mul AN, et al. Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum Genet 2010; 128:529.</a></li><li class="breakAll">https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/ (Accessed on January 11, 2018).</li><li><a class="nounderline abstract_t">Nie Q, Shrestha S, Tapper EE, et al. Quantitative Contribution of rs75017182 to Dihydropyrimidine Dehydrogenase mRNA Splicing and Enzyme Activity. Clin Pharmacol Ther 2017; 102:662.</a></li><li><a class="nounderline abstract_t">Lee AM, Shi Q, Alberts SR, et al. Association between DPYD c.1129-5923 C&gt;G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet Genomics 2016; 26:133.</a></li><li><a class="nounderline abstract_t">Mattison LK, Fourie J, Desmond RA, et al. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 2006; 12:5491.</a></li><li><a class="nounderline abstract_t">Caudle KE, Thorn CF, Klein TE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther 2013; 94:640.</a></li><li><a class="nounderline abstract_t">Zhou Y, Dagli Hernandez C, Lauschke VM. Population-scale predictions of DPD and TPMT phenotypes using a quantitative pharmacogene-specific ensemble classifier. Br J Cancer 2020; 123:1782.</a></li><li><a class="nounderline abstract_t">Ezzeldin HH, Lee AM, Mattison LK, Diasio RB. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res 2005; 11:8699.</a></li><li><a class="nounderline abstract_t">Amstutz U, Offer SM, Sistonen J, et al. Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy. Clin Cancer Res 2015; 21:2038.</a></li><li><a class="nounderline abstract_t">Lee AM, Shi Q, Pavey E, et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst 2014; 106.</a></li><li><a class="nounderline abstract_t">Henricks LM, Lunenburg CATC, de Man FM, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol 2018; 19:1459.</a></li><li><a class="nounderline abstract_t">Henricks LM, Lunenburg CATC, de Man FM, et al. A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy. Eur J Cancer 2019; 107:60.</a></li><li><a class="nounderline abstract_t">Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther 2018; 103:210.</a></li><li class="breakAll">Updated guidance from the Clinical Pharmacogenitics Implementation Consortium is available at https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/ (Accessed on July 17, 2020).</li><li><a class="nounderline abstract_t">Ciccolini J. DPD deficiency in patients treated with fluorouracil. Lancet Oncol 2015; 16:1574.</a></li><li class="breakAll">https://www.esmo.org/oncology-news/ema-provides-new-testing-and-treatment-recommendations-for-fluorouracil-capecitabine-and-tegafur (Accessed on July 17, 2020).</li><li><a class="nounderline abstract_t">Argilés G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31:1291.</a></li><li><a class="nounderline abstract_t">Mandola MV, Stoehlmacher J, Muller-Weeks S, et al. A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003; 63:2898.</a></li><li><a class="nounderline abstract_t">Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001; 1:65.</a></li><li><a class="nounderline abstract_t">Thomas F, Hoskins JM, Dvorak A, et al. Detection of the G&gt;C SNP and rare mutations in the 28-bp repeat of TYMS using gel-based capillary electrophoresis. Pharmacogenomics 2010; 11:1751.</a></li><li><a class="nounderline abstract_t">Lincz LF, Scorgie FE, Garg MB, Ackland SP. Identification of a novel single nucleotide polymorphism in the first tandem repeat sequence of the thymidylate synthase 2R allele. Int J Cancer 2007; 120:1930.</a></li><li><a class="nounderline abstract_t">Gusella M, Bolzonella C, Crepaldi G, et al. A novel G/C single-nucleotide polymorphism in the double 28-bp repeat thymidylate synthase allele. Pharmacogenomics J 2006; 6:421.</a></li><li><a class="nounderline abstract_t">de Bock CE, Garg MB, Scott N, et al. Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo. Pharmacogenomics J 2011; 11:307.</a></li><li><a class="nounderline abstract_t">Meulendijks D, Jacobs BA, Aliev A, et al. Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G to C substitution in the first 28-bp tandem repeat of the thymidylate synthase 2R allele. Int J Cancer 2016; 138:245.</a></li><li><a class="nounderline abstract_t">Ichikawa W, Takahashi T, Suto K, et al. Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. Clin Cancer Res 2006; 12:3928.</a></li><li><a class="nounderline abstract_t">Lecomte T, Ferraz JM, Zinzindohoué F, et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 2004; 10:5880.</a></li><li><a class="nounderline abstract_t">Rosmarin D, Palles C, Church D, et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 2014; 32:1031.</a></li><li><a class="nounderline abstract_t">Sharma R, Hoskins JM, Rivory LP, et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin Cancer Res 2008; 14:817.</a></li><li><a class="nounderline abstract_t">Ezzeldin HH, Diasio RB. Predicting fluorouracil toxicity: can we finally do it? J Clin Oncol 2008; 26:2080.</a></li><li><a class="nounderline abstract_t">Braun MS, Richman SD, Thompson L, et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol 2009; 27:5519.</a></li><li><a class="nounderline abstract_t">Haller DG, Cassidy J, Clarke SJ, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008; 26:2118.</a></li><li><a class="nounderline abstract_t">Lewis CJ, Crane NT, Wilson DB, Yetley EA. Estimated folate intakes: data updated to reflect food fortification, increased bioavailability, and dietary supplement use. Am J Clin Nutr 1999; 70:198.</a></li><li><a class="nounderline abstract_t">Thirion P, Michiels S, Pignon JP, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22:3766.</a></li><li><a class="nounderline abstract_t">Sharma R, Rivory L, Beale P, et al. A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. Br J Cancer 2006; 94:964.</a></li><li><a class="nounderline abstract_t">Hertz DL. Assessment of the Clinical Utility of Pretreatment DPYD Testing for Patients Receiving Fluoropyrimidine Chemotherapy. J Clin Oncol 2022; 40:3882.</a></li><li class="breakAll">Wagner M, Eichmeyer J, Montgomery PG, et al. Delivering pharmacogenetic testing in the Community Setting. Oncology Issues. September-October 2016; PDF available online at http://www.nxtbook.com/nxtbooks/accc/oncologyissues_20160910/#/32 (Accessed on October 11, 2016).</li><li><a class="nounderline abstract_t">Yen JL, McLeod HL. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer 2007; 43:1011.</a></li><li><a class="nounderline abstract_t">van Kuilenburg AB. Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question. Cancer Invest 2006; 24:215.</a></li><li><a class="nounderline abstract_t">Martens FK, Huntjens DW, Rigter T, et al. DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice. Front Pharmacol 2019; 10:1609.</a></li><li><a class="nounderline abstract_t">Reizine NM, Danahey K, Truong TM, et al. Clinically actionable genotypes for anticancer prescribing among &gt;1500 patients with pharmacogenomic testing. Cancer 2022; 128:1649.</a></li><li><a class="nounderline abstract_t">Koo K, Pasternak AL, Henry NL, et al. Survey of US Medical Oncologists' Practices and Beliefs Regarding DPYD Testing Before Fluoropyrimidine Chemotherapy. JCO Oncol Pract 2022; 18:e958.</a></li><li><a class="nounderline abstract_t">Launay M, Dahan L, Duval M, et al. Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer. Br J Clin Pharmacol 2016; 81:124.</a></li><li><a class="nounderline abstract_t">Etienne-Grimaldi MC, Boyer JC, Beroud C, et al. New advances in DPYD genotype and risk of severe toxicity under capecitabine. PLoS One 2017; 12:e0175998.</a></li><li><a class="nounderline abstract_t">Meulendijks D, Henricks LM, Jacobs BAW, et al. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. Br J Cancer 2017; 116:1415.</a></li><li><a class="nounderline abstract_t">Wilson KS, Fitzgerald CA, Barnett JB, et al. Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience. Cancer Invest 2007; 25:711.</a></li><li><a class="nounderline abstract_t">Deenen MJ, Terpstra WE, Cats A, et al. Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine. Ann Intern Med 2010; 153:767.</a></li><li><a class="nounderline abstract_t">Ma WW, Saif MW, El-Rayes BF, et al. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. Cancer 2017; 123:345.</a></li><li class="breakAll">Ma WW, Saif WM, El-Rayes BF, et al. Clinical trial experience with uridine triacetate for 5-fluorouracil toxicity (abstract). J Clin Oncol 34, 2016 (suppl 4S; abstr 655). http://meetinglibrary.asco.org/content/159120-173 (Accessed on February 04, 2016).</li><li class="breakAll">von Borstel R, O'Neil JD, Saydoff JA, et al. Uridine triacetate for lethal 5-FU toxicity due to dihydropyrimidine dehydrogenase (DPD) deficiency (abstract). J Clin Oncol 2010 (suppl abstract e13505).</li><li class="breakAll">http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm476930.htm (Accessed on December 14, 2015).</li><li><a class="nounderline abstract_t">Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25:4779.</a></li><li><a class="nounderline abstract_t">Rothenberg ML, Cox JV, Butts C, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008; 19:1720.</a></li><li><a class="nounderline abstract_t">Cassidy J, Clarke S, Díaz-Rubio E, et al. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 2011; 105:58.</a></li><li class="breakAll">DailyMed Drug Information: https://dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on December 25, 2023).</li><li><a class="nounderline abstract_t">O'Donnell PH, Stark AL, Gamazon ER, et al. Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer 2012; 118:4063.</a></li><li><a class="nounderline abstract_t">Gajria D, Feigin K, Tan LK, et al. Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer. Cancer 2011; 117:4125.</a></li><li><a class="nounderline abstract_t">Gajria D, Gonzalez J, Feigin K, et al. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2012; 131:111.</a></li><li><a class="nounderline abstract_t">Sulkes A, Benner SE, Canetta RM. Uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer. J Clin Oncol 1998; 16:3461.</a></li><li><a class="nounderline abstract_t">Takiuchi H, Ajani JA. Uracil-tegafur in gastric carcinoma: a comprehensive review. J Clin Oncol 1998; 16:2877.</a></li><li><a class="nounderline abstract_t">Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993; 53:4004.</a></li><li><a class="nounderline abstract_t">Takechi T, Nakano K, Uchida J, et al. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 1997; 39:205.</a></li><li><a class="nounderline abstract_t">Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357:1810.</a></li><li><a class="nounderline abstract_t">Hamaguchi T, Shimada Y, Mizusawa J, et al. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial. Lancet Gastroenterol Hepatol 2018; 3:47.</a></li><li><a class="nounderline abstract_t">Yamada Y, Takahari D, Matsumoto H, et al. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 2013; 14:1278.</a></li><li><a class="nounderline abstract_t">Hong YS, Park YS, Lim HY, et al. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Lancet Oncol 2012; 13:1125.</a></li><li><a class="nounderline abstract_t">Saliba F, Hagipantelli R, Misset JL, et al. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol 1998; 16:2745.</a></li><li><a class="nounderline abstract_t">Hecht JR. Gastrointestinal toxicity or irinotecan. Oncology (Williston Park) 1998; 12:72.</a></li><li><a class="nounderline abstract_t">Pazdur R. Irinotecan: toward clinical end points in drug development. Oncology (Williston Park) 1998; 12:13.</a></li><li><a class="nounderline abstract_t">Rothenberg ML. CPT-11: an original spectrum of clinical activity. Semin Oncol 1996; 23:21.</a></li><li><a class="nounderline abstract_t">Abigerges D, Armand JP, Chabot GG, et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994; 86:446.</a></li><li><a class="nounderline abstract_t">Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003; 21:807.</a></li><li><a class="nounderline abstract_t">Sanoff HK, Sargent DJ, Green EM, et al. Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol 2009; 27:4109.</a></li><li><a class="nounderline abstract_t">Gupta E, Lestingi TM, Mick R, et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994; 54:3723.</a></li><li><a class="nounderline abstract_t">Wasserman E, Myara A, Lokiec F, et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 1997; 8:1049.</a></li><li><a class="nounderline abstract_t">Takasuna K, Hagiwara T, Hirohashi M, et al. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996; 56:3752.</a></li><li><a class="nounderline abstract_t">Karas S, Innocenti F. All You Need to Know About UGT1A1 Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide. JCO Oncol Pract 2022; 18:270.</a></li><li><a class="nounderline abstract_t">Palomaki GE, Bradley LA, Douglas MP, et al. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med 2009; 11:21.</a></li><li><a class="nounderline abstract_t">Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905.</a></li><li><a class="nounderline abstract_t">Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041.</a></li><li><a class="nounderline abstract_t">Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001; 345:144.</a></li><li><a class="nounderline abstract_t">Rothenberg ML, Meropol NJ, Poplin EA, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19:3801.</a></li><li><a class="nounderline abstract_t">Delaunoit T, Goldberg RM, Sargent DJ, et al. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer 2004; 101:2170.</a></li><li><a class="nounderline abstract_t">Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229.</a></li><li><a class="nounderline abstract_t">Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23:4866.</a></li><li><a class="nounderline abstract_t">Chang TC, Shiah HS, Yang CH, et al. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. Cancer Chemother Pharmacol 2015; 75:579.</a></li><li class="breakAll">Chen L-T, Von Hoff DD, Li C-P, et al. Expanded analysis of NAPOLI-1: Phase 3 study of MM-398 (nal-IRI_ with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy (abstr). J Clin Oncol 33, 2015 (suppl 3; abstr 234). Liposomal irinotecan (Accessed on October 22, 2015).</li><li><a class="nounderline abstract_t">Pectasides D, Papaxoinis G, Kalogeras KT, et al. XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis. BMC Cancer 2012; 12:271.</a></li><li><a class="nounderline abstract_t">Xu RH, Muro K, Morita S, et al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19:660.</a></li><li><a class="nounderline abstract_t">de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938.</a></li><li><a class="nounderline abstract_t">Scheithauer W, Kornek GV, Raderer M, et al. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. J Clin Oncol 1999; 17:902.</a></li><li><a class="nounderline abstract_t">Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23.</a></li><li><a class="nounderline abstract_t">André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343.</a></li><li><a class="nounderline abstract_t">Díaz-Rubio E, Tabernero J, Gómez-España A, et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007; 25:4224.</a></li><li><a class="nounderline abstract_t">Grothey A, Sobrero AF, Shields AF, et al. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N Engl J Med 2018; 378:1177.</a></li><li><a class="nounderline abstract_t">Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364:1817.</a></li><li><a class="nounderline abstract_t">Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med 2018; 379:2395.</a></li><li><a class="nounderline abstract_t">Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014; 371:1609.</a></li><li><a class="nounderline abstract_t">Cremolini C, Antoniotti C, Rossini D, et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 2020; 21:497.</a></li><li><a class="nounderline abstract_t">Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589.</a></li><li><a class="nounderline abstract_t">Rusthoven JJ, Eisenhauer E, Butts C, et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999; 17:1194.</a></li><li><a class="nounderline abstract_t">Taylor P, Castagneto B, Dark G, et al. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol 2008; 3:764.</a></li><li><a class="nounderline abstract_t">Paz-Ares L, Mezger J, Ciuleanu TE, et al. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol 2015; 16:328.</a></li><li><a class="nounderline abstract_t">Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med 2017; 376:629.</a></li><li><a class="nounderline abstract_t">Zukin M, Barrios CH, Pereira JR, et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol 2013; 31:2849.</a></li><li><a class="nounderline abstract_t">Pivot X, Koralewski P, Hidalgo JL, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008; 19:1547.</a></li><li><a class="nounderline abstract_t">Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009; 15:723.</a></li><li><a class="nounderline abstract_t">de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147.</a></li><li><a class="nounderline abstract_t">Nieuweboer AJ, de Graan AM, Hamberg P, et al. Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study. Clin Cancer Res 2017; 23:1679.</a></li><li><a class="nounderline abstract_t">Eisenberger M, Hardy-Bessard AC, Kim CS, et al. Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. J Clin Oncol 2017; 35:3198.</a></li><li><a class="nounderline abstract_t">Oudard S, Fizazi K, Sengeløv L, et al. Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. J Clin Oncol 2017; 35:3189.</a></li><li><a class="nounderline abstract_t">Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502.</a></li><li><a class="nounderline abstract_t">Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 2018; 379:2108.</a></li><li><a class="nounderline abstract_t">Schmid P, Abraham J, Chan S, et al. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. J Clin Oncol 2020; 38:423.</a></li><li><a class="nounderline abstract_t">Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019; 393:1948.</a></li><li><a class="nounderline abstract_t">Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003; 8:508.</a></li><li><a class="nounderline abstract_t">Harvey RD. Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib. Clin Pharmacol 2014; 6:87.</a></li><li><a class="nounderline abstract_t">Offidani M, Corvatta L, Caraffa P, et al. An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma. Onco Targets Ther 2014; 7:1793.</a></li><li><a class="nounderline abstract_t">Mann BS, Johnson JR, Cohen MH, et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12:1247.</a></li><li class="breakAll">Prescribing information for belinostat available online at http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206256lbl.pdf?et_cid=34049616&amp;et_rid=789337055&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2014%2f206256lbl.pdf (Accessed on July 11, 2014).</li><li><a class="nounderline abstract_t">Pawlyn C, Khan MS, Muls A, et al. Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. Blood 2014; 124:2467.</a></li><li><a class="nounderline abstract_t">Shah NT, Kris MG, Pao W, et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 2005; 23:165.</a></li><li><a class="nounderline abstract_t">Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 2017; 18:1454.</a></li><li><a class="nounderline abstract_t">Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378:113.</a></li><li><a class="nounderline abstract_t">Ellis PM, Shepherd FA, Millward M, et al. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. Lancet Oncol 2014; 15:1379.</a></li><li><a class="nounderline abstract_t">Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31:3327.</a></li><li class="breakAll">Mobocertinib: United States Food and Drug Administration Prescribing Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215310s003lbl.pdf (Accessed on September 27, 2023).</li><li><a class="nounderline abstract_t">Cohen EE, Halpern AB, Kasza K, et al. Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncol 2009; 45:e155.</a></li><li><a class="nounderline abstract_t">Thomas SK, Fossella FV, Liu D, et al. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer 2006; 7:326.</a></li><li><a class="nounderline abstract_t">Messersmith WA, Laheru DA, Senzer NN, et al. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clin Cancer Res 2004; 10:6522.</a></li><li><a class="nounderline abstract_t">Czito BG, Willett CG, Bendell JC, et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol 2006; 24:656.</a></li><li><a class="nounderline abstract_t">Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24:4914.</a></li><li><a class="nounderline abstract_t">Hanna N, Lilenbaum R, Ansari R, et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 2006; 24:5253.</a></li><li><a class="nounderline abstract_t">Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201.</a></li><li><a class="nounderline abstract_t">Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337.</a></li><li><a class="nounderline abstract_t">Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357:2040.</a></li><li><a class="nounderline abstract_t">Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658.</a></li><li><a class="nounderline abstract_t">Hecht JR, Patnaik A, Berlin J, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007; 110:980.</a></li><li class="breakAll">ZYDELIG (idelalisib) tablets, for oral use. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205858lbl.pdf (Accessed on July 30, 2014).</li><li><a class="nounderline abstract_t">Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 2014; 123:3406.</a></li><li><a class="nounderline abstract_t">Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014; 370:1008.</a></li><li><a class="nounderline abstract_t">Flinn IW, O'Brien S, Kahl B, et al. Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. Blood 2018; 131:877.</a></li><li class="breakAll">United States Prescribing information for duvelisib available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf (Accessed on September 27, 2018).</li><li><a class="nounderline abstract_t">Davids MS, Kuss BJ, Hillmen P, et al. Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. Clin Cancer Res 2020; 26:2096.</a></li><li><a class="nounderline abstract_t">André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2019; 380:1929.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115.</a></li><li><a class="nounderline abstract_t">Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389:56.</a></li><li><a class="nounderline abstract_t">Hutson TE, Lesovoy V, Al-Shukri S, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 2013; 14:1287.</a></li><li><a class="nounderline abstract_t">van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379:1879.</a></li><li><a class="nounderline abstract_t">Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 2018; 379:54.</a></li><li><a class="nounderline abstract_t">Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015; 372:621.</a></li><li><a class="nounderline abstract_t">Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012; 30:134.</a></li><li><a class="nounderline abstract_t">Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003; 21:1637.</a></li><li><a class="nounderline abstract_t">Nishiwaki S, Maeda M, Yamada M, et al. Clinical efficacy of fecal occult blood test and colonoscopy for dasatinib-induced hemorrhagic colitis in CML patients. Blood 2017; 129:126.</a></li><li class="breakAll">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6093952a-5248-45cb-ad17-33716a411146.</li><li class="breakAll">Ripretinib tablets. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf (Accessed on May 19, 2020).</li><li class="breakAll">Bosutinib tablets. United States Prescribing Information. US National Library of Medicine. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl.pdf?et_cid=29953027&amp;et_rid=463638624&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2012%2f203341lbl.pdf (Accessed on September 05, 2012).</li><li><a class="nounderline abstract_t">Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012; 367:2075.</a></li><li><a class="nounderline abstract_t">Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013; 369:1783.</a></li><li><a class="nounderline abstract_t">Azim HA Jr, Agbor-Tarh D, Bradbury I, et al. Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial. J Clin Oncol 2013; 31:4504.</a></li><li><a class="nounderline abstract_t">Cortés J, Fumoleau P, Bianchi GV, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012; 30:1594.</a></li><li><a class="nounderline abstract_t">Swain SM, Schneeweiss A, Gianni L, et al. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. Ann Oncol 2017; 28:761.</a></li><li><a class="nounderline abstract_t">Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017; 18:1688.</a></li><li><a class="nounderline abstract_t">Barcenas CH, Hurvitz SA, Di Palma JA, et al. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial. Ann Oncol 2020; 31:1223.</a></li><li class="breakAll">Tucatinib: US Food and Drug Administration Prescribing Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf (Accessed on January 23, 2023).</li><li><a class="nounderline abstract_t">Murthy RK, Loi S, Okines A, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med 2020; 382:597.</a></li><li><a class="nounderline abstract_t">Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 2017; 35:3638.</a></li><li><a class="nounderline abstract_t">Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol 2017; 35:2875.</a></li><li><a class="nounderline abstract_t">Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med 2020; 382:514.</a></li><li><a class="nounderline abstract_t">Im SA, Lu YS, Bardia A, et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med 2019; 381:307.</a></li><li><a class="nounderline abstract_t">Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 2016; 375:1925.</a></li><li><a class="nounderline abstract_t">Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367:1783.</a></li><li><a class="nounderline abstract_t">Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med 2020; 382:610.</a></li><li><a class="nounderline abstract_t">Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med 2019; 380:741.</a></li><li class="breakAll">Sacituzumab govitecan-hziy for injection. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf (Accessed on February 15, 2023).</li><li><a class="nounderline abstract_t">Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449.</a></li><li><a class="nounderline abstract_t">Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271.</a></li><li><a class="nounderline abstract_t">Jerusalem G, de Boer RH, Hurvitz S, et al. Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial. JAMA Oncol 2018; 4:1367.</a></li><li><a class="nounderline abstract_t">Peters S, Camidge DR, Shaw AT, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2017; 377:829.</a></li><li><a class="nounderline abstract_t">Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013; 31:482.</a></li><li><a class="nounderline abstract_t">Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367:107.</a></li><li class="breakAll">http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206192s000lbl.pdf (Accessed on November 20, 2015).</li><li><a class="nounderline abstract_t">Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med 2015; 373:2425.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/210259s000lbl.pdf (Accessed on November 02, 2017).</li><li><a class="nounderline abstract_t">Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet 2020; 395:1278.</a></li><li><a class="nounderline abstract_t">Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med 2019; 381:317.</a></li><li><a class="nounderline abstract_t">Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366:1382.</a></li><li><a class="nounderline abstract_t">Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 390:1949.</a></li><li><a class="nounderline abstract_t">González-Martín A, Pothuri B, Vergote I, et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med 2019; 381:2391.</a></li><li><a class="nounderline abstract_t">Bhalme M, Hayes S, Norton A, et al. Rituximab-associated colitis. Inflamm Bowel Dis 2013; 19:E41.</a></li><li><a class="nounderline abstract_t">Larkin PJ, Cherny NI, La Carpia D, et al. Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2018; 29:iv111.</a></li><li><a class="nounderline abstract_t">Talley NJ, Phillips SF, Haddad A, et al. GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci 1990; 35:477.</a></li><li><a class="nounderline abstract_t">Davies A, Leach C, Caponero R, et al. MASCC recommendations on the management of constipation in patients with advanced cancer. Support Care Cancer 2020; 28:23.</a></li><li><a class="nounderline abstract_t">Sharma RK. Vincristine and gastrointestinal transit. Gastroenterology 1988; 95:1435.</a></li><li><a class="nounderline abstract_t">Legha SS. Vincristine neurotoxicity. Pathophysiology and management. Med Toxicol 1986; 1:421.</a></li><li><a class="nounderline abstract_t">Holland JF, Scharlau C, Gailani S, et al. Vincristine treatment of advanced cancer: a cooperative study of 392 cases. Cancer Res 1973; 33:1258.</a></li><li><a class="nounderline abstract_t">Anderson H, Scarffe JH, Lambert M, et al. VAD chemotherapy--toxicity and efficacy--in patients with multiple myeloma and other lymphoid malignancies. Hematol Oncol 1987; 5:213.</a></li><li><a class="nounderline abstract_t">Hohneker JA. A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin Oncol 1994; 21:42.</a></li><li><a class="nounderline abstract_t">Haim N, Epelbaum R, Ben-Shahar M, et al. Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer 1994; 73:2515.</a></li><li><a class="nounderline abstract_t">Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565.</a></li><li><a class="nounderline abstract_t">Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000; 18:708.</a></li><li><a class="nounderline abstract_t">Dimopoulos MA, Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 2004; 117:508.</a></li><li><a class="nounderline abstract_t">Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357:2133.</a></li><li><a class="nounderline abstract_t">Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357:2123.</a></li><li class="breakAll">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be.</li><li class="breakAll">United States Prescribing Information for pomalidomide available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204026lbl.pdf?et_cid=31038989&amp;et_rid=463638624&amp;linkid=www.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2013%2f204026lbl.pdf (Accessed on February 12, 2013).</li><li><a class="nounderline abstract_t">Natale RB, Thongprasert S, Greco FA, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011; 29:1059.</a></li><li><a class="nounderline abstract_t">Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010; 95:2664.</a></li><li class="breakAll">Wells, SA, Robinson, BG, Gagel, RRF, et al. Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA) (Abstract 5503). J Clin Oncol 2010; 28:421s. Abstract available online at http://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=74&amp;abstractID=50718 (Accessed on April 25, 2011).</li><li><a class="nounderline abstract_t">Tarumi Y, Wilson MP, Szafran O, Spooner GR. Randomized, double-blind, placebo-controlled trial of oral docusate in the management of constipation in hospice patients. J Pain Symptom Manage 2013; 45:2.</a></li><li><a class="nounderline abstract_t">Arnold D, Fuchs CS, Tabernero J, et al. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Ann Oncol 2017; 28:2932.</a></li><li><a class="nounderline abstract_t">Gotlieb WH, Amant F, Advani S, et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2012; 13:154.</a></li><li><a class="nounderline abstract_t">Chekerov R, Hilpert F, Mahner S, et al. Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2018; 19:1247.</a></li><li><a class="nounderline abstract_t">Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014; 370:699.</a></li><li><a class="nounderline abstract_t">Kabbinavar FF, Flynn PJ, Kozloff M, et al. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study. Eur J Cancer 2012; 48:1126.</a></li><li><a class="nounderline abstract_t">McClay H, Cervi P. Thalidomide and bowel perforation: four cases in one hospital. Br J Haematol 2008; 140:360.</a></li><li class="breakAll">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=827d60e8-7e07-41b7-c28b-49ef1c4a5a41.</li><li class="breakAll">United States Prescribing Information for trametinib available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204114s006lbl.pdf (Accessed on March 16, 2017).</li></ol></div><div id="topicVersionRevision">Topic 2824 Version 109.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19258191" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Acute and long-term gastrointestinal consequences of chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Colonic histological changes induced by 5-fluorouracil</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7494232" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12911669" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18998135" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Irinotecan-induced mucositis is associated with changes in intestinal mucins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1651156" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18685389" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Tyrosine kinase inhibitors and gut toxicity: a new era in supportive care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18349858" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8843722" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Epidermal growth factor inhibits Ca(2+)-dependent Cl- transport in T84 human colonic epithelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8062196" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Chemotherapy-induced lactose intolerance in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15290663" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6428327" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Small bowel function in acute lymphoblastic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7714685" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prospective study of lactose absorption during cancer chemotherapy: feasibility of a yogurt-supplemented diet in lactose malabsorbers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32033152" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Consumption of Lactose, Other FODMAPs and Diarrhoea during Adjuvant 5-Fluorouracil Chemotherapy for Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7799022" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20676744" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24957587" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : An unusual case of bowel perforation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15175435" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18421054" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32284253" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10884503" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17023562" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Diarrhea in neutropenic patients: a prospective cohort study with emphasis on neutropenic enterocolitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20862749" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Incidence and risk factors for lower alimentary tract mucositis after 1529 courses of chemotherapy in a homogenous population of oncology patients: clinical and research implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10675076" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10902651" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Colitis and docetaxel-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8353229" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clostridium difficile infection associated with antineoplastic chemotherapy: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8641617" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1497405" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clostridium difficile diarrhea induced by cancer chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9784328" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26490656" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3309201" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Severe life-threatening toxicities observed in study using leucovorin with 5-fluorouracil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2443619" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7751875" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2476530" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2674331" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15689586" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Systemic therapy for colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9257428" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17311702" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17853393" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11896096" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15693031" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3335642" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11953843" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12912951" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1648430" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9816193" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15377401" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10537327" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14555507" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20204365" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17121937" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12542909" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24648345" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11384742" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11895907" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18299612" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12209976" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g&gt;a mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11555601" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12360106" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : High prevalence of the IVS14 + 1G&gt;A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21498394" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23736036" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26573078" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23930673" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : DPYD IVS14+1G&gt;A and 2846A&gt;T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26603945" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Clinical relevance of DPYD variants c.1679T&gt;G, c.1236G&gt;A/HapB3, and c.1601G&gt;A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19530960" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27544765" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Patients homozygous for DPYD c.1129-5923C&gt;G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20803296" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20803296" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28295243" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Quantitative Contribution of rs75017182 to Dihydropyrimidine Dehydrogenase mRNA Splicing and Enzyme Activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26658227" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Association between DPYD c.1129-5923 C&gt;G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17000684" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23988873" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32973300" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Population-scale predictions of DPD and TPMT phenotypes using a quantitative pharmacogene-specific ensemble classifier.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16361556" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25655103" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25381393" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30348537" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30544060" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29152729" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29152729" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26603944" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : DPD deficiency in patients treated with fluorouracil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26603944" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : DPD deficiency in patients treated with fluorouracil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32702383" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12782596" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11913730" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21142919" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Detection of the G&gt;C SNP and rare mutations in the 28-bp repeat of TYMS using gel-based capillary electrophoresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17278107" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Identification of a novel single nucleotide polymorphism in the first tandem repeat sequence of the thymidylate synthase 2R allele.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16868573" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : A novel G/C single-nucleotide polymorphism in the double 28-bp repeat thymidylate synthase allele.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20531375" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26189437" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G to C substitution in the first 28-bp tandem repeat of the thymidylate synthase 2R allele.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16818689" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15355920" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24590654" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18245544" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18299611" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Predicting fluorouracil toxicity: can we finally do it?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19858398" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18445840" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Potential regional differences for the tolerability profiles of fluoropyrimidines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10426695" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Estimated folate intakes: data updated to reflect food fortification, increased bioavailability, and dietary supplement use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15365073" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16552436" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36108264" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Assessment of the Clinical Utility of Pretreatment DPYD Testing for Patients Receiving Fluoropyrimidine Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36108264" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Assessment of the Clinical Utility of Pretreatment DPYD Testing for Patients Receiving Fluoropyrimidine Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17350823" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Should DPD analysis be required prior to prescribing fluoropyrimidines?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16537192" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32047438" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35090043" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Clinically actionable genotypes for anticancer prescribing among&gt;1500 patients with pharmacogenomic testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35239419" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Survey of US Medical Oncologists' Practices and Beliefs Regarding DPYD Testing Before Fluoropyrimidine Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26392323" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28481884" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : New advances in DPYD genotype and risk of severe toxicity under capecitabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28427087" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18058467" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21135311" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27622829" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27622829" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27622829" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27622829" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17947725" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18550577" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21673685" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21673685" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22864933" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Identification of novel germline polymorphisms governing capecitabine sensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21387266" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21898114" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9779725" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9704742" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Uracil-tegafur in gastric carcinoma: a comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7689420" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8996521" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17978289" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29079411" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24225157" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23062232" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9704727" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9726096" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Gastrointestinal toxicity or irinotecan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9726086" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Irinotecan: toward clinical end points in drug development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8633249" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : CPT-11: an original spectrum of clinical activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8120919" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12610178" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19636001" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8033091" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9402181" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8706020" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34860573" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : All You Need to Know About UGT1A1 Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19125129" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11006366" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10744089" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11450666" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11559717" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15470715" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14657227" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15939922" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25577133" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25577133" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22748098" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29555258" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10944126" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10071282" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14665611" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15175436" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17548839" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29590544" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21561347" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30575490" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25337750" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32164906" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15117980" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10561178" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18594323" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25701171" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27959700" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23775961" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18436520" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19147780" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20888992" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27702823" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28809610" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28753384" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15470213" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30345906" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31841354" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30982686" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14657528" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24855395" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25302026" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17962618" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17962618" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25301337" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15557594" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Practical management of patients with non-small-cell lung cancer treated with gefitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28958502" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29151359" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25439692" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23816960" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23816960" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19586795" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16640804" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15475439" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16446337" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17050875" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17114658" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14993230" id="rid198" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>199 : Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15269313" id="rid199" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>200 : Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18003960" id="rid200" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>201 : Cetuximab for the treatment of colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17470858" id="rid201" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>202 : Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17671985" id="rid202" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>203 : Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17671985" id="rid203" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>204 : Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24615776" id="rid204" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>205 : Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24450858" id="rid205" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>206 : PI3Kδinhibition by idelalisib in patients with relapsed indolent lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29191916" id="rid206" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>207 : Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29191916" id="rid207" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>208 : Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31964785" id="rid208" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>209 : Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31091374" id="rid209" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>210 : Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17215529" id="rid210" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>211 : Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27932229" id="rid211" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>212 : Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24206640" id="rid212" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>213 : Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22595799" id="rid213" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>214 : Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29972759" id="rid214" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>215 : Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25671254" id="rid215" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>216 : Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22025146" id="rid216" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>217 : Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12668652" id="rid217" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>218 : Practical management of patients with chronic myeloid leukemia receiving imatinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27864292" id="rid218" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>219 : Clinical efficacy of fecal occult blood test and colonoscopy for dasatinib-induced hemorrhagic colitis in CML patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27864292" id="rid219" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>220 : Clinical efficacy of fecal occult blood test and colonoscopy for dasatinib-induced hemorrhagic colitis in CML patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27864292" id="rid220" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>221 : Clinical efficacy of fecal occult blood test and colonoscopy for dasatinib-induced hemorrhagic colitis in CML patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27864292" id="rid221" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>222 : Clinical efficacy of fecal occult blood test and colonoscopy for dasatinib-induced hemorrhagic colitis in CML patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23190221" id="rid222" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>223 : Ponatinib in refractory Philadelphia chromosome-positive leukemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24180494" id="rid223" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>224 : A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24248687" id="rid224" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>225 : Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22393084" id="rid225" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>226 : Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28057664" id="rid226" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>227 : Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29146401" id="rid227" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>228 : Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32464281" id="rid228" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>229 : Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32464281" id="rid229" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>230 : Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31825569" id="rid230" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>231 : Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28968163" id="rid231" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>232 : MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28580882" id="rid232" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>233 : MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31826360" id="rid233" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>234 : Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31166679" id="rid234" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>235 : Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27959613" id="rid235" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>236 : Palbociclib and Letrozole in Advanced Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23020162" id="rid236" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>237 : Trastuzumab emtansine for HER2-positive advanced breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31825192" id="rid237" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>238 : Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30786188" id="rid238" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>239 : Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30786188" id="rid239" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>240 : Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18653228" id="rid240" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>241 : Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17538086" id="rid241" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>242 : Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29862411" id="rid242" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>243 : Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28586279" id="rid243" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>244 : Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23248257" id="rid244" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>245 : Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22663011" id="rid245" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>246 : Improved survival with MEK inhibition in BRAF-mutated melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22663011" id="rid246" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>247 : Improved survival with MEK inhibition in BRAF-mutated melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26639149" id="rid247" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>248 : Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26639149" id="rid248" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>249 : Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32305093" id="rid249" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>250 : Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31157963" id="rid250" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>251 : Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22452356" id="rid251" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>252 : Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28916367" id="rid252" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>253 : Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31562799" id="rid253" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>254 : Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22488947" id="rid254" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>255 : Rituximab-associated colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30016389" id="rid255" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>256 : Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2138532" id="rid256" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>257 : GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31396746" id="rid257" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>258 : MASCC recommendations on the management of constipation in patients with advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3169508" id="rid258" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>259 : Vincristine and gastrointestinal transit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3540519" id="rid259" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>260 : Vincristine neurotoxicity. Pathophysiology and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4352365" id="rid260" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>261 : Vincristine treatment of advanced cancer: a cooperative study of 392 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3115884" id="rid261" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>262 : VAD chemotherapy--toxicity and efficacy--in patients with multiple myeloma and other lymphoid malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7973769" id="rid262" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>263 : A summary of vinorelbine (Navelbine) safety data from North American clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8174048" id="rid263" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>264 : Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10564685" id="rid264" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>265 : Antitumor activity of thalidomide in refractory multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10673511" id="rid265" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>266 : Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15464708" id="rid266" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>267 : Adverse effects of thalidomide administration in patients with neoplastic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18032763" id="rid267" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>268 : Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18032762" id="rid268" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>269 : Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18032762" id="rid269" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>270 : Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18032762" id="rid270" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>271 : Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21282542" id="rid271" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>272 : Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20371662" id="rid272" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>273 : Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20371662" id="rid273" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>274 : Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22889861" id="rid274" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>275 : Randomized, double-blind, placebo-controlled trial of oral docusate in the management of constipation in hospice patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28950290" id="rid275" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>276 : Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22192729" id="rid276" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>277 : Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30100379" id="rid277" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>278 : Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24552317" id="rid278" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>279 : A randomized trial of bevacizumab for newly diagnosed glioblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22424880" id="rid279" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>280 : Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18042266" id="rid280" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>281 : Thalidomide and bowel perforation: four cases in one hospital.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
